CLINICAL AND MEDICINAL APPLICATIONS OF RESVERATROL -A REVIEW
药物合成英语
药物合成英语Title: Medicinal Drug SynthesisIntroduction:Medicinal drug synthesis refers to the process of designing and producing pharmaceutical compounds through various chemical reactions. This highly complex and rigorous procedure involves a series of carefully controlled steps, enabling the creation of active ingredients in drugs and medications. Through drug synthesis, scientists and chemists aim to discover, optimize, and improve therapeutic agents for the treatment of various diseases and medical conditions. This article explores the key aspects and stages involved in the synthesis of medicinal drugs.1. Drug Discovery:Drug discovery marks the initial stage of medicinal drug synthesis. Scientists and researchers work to identifypotential drug candidates with the desired pharmacological properties. This involves studying the biological pathways and targets of diseases, screening compound libraries, and conducting extensive research to identify molecules that interact with specific disease targets.2. Drug Design:Once potential drug candidates are identified, the drug design stage commences. This process involves utilizing computer-aided design (CAD) software, molecular modeling, and computational chemistry techniques to create and optimize the chemical structures of the drug molecules. Researchers focus on enhancing the drug's potency, selectivity, and bioavailability while minimizing adverse effects.3. Chemical Synthesis:The chemical synthesis phase involves the actual preparation of the drug molecules. Chemical reactions are employed to transform readily available starting materialsinto the desired drug compound. Organic chemistry principles and techniques, such as functional group transformations and multi-step synthesis, are crucial in achieving the desired chemical transformations.4. Process Development:Process development aims to optimize the chemical synthesis on a larger scale. Researchers strive to establish efficient and cost-effective methods that can be easily scaled up for commercial production. Factors such as reaction conditions, catalysts, purification techniques, and yield optimization are carefully considered during this stage.5. Analytical Testing:Analytical testing is an integral part of drug synthesis. Numerous analytical techniques, including spectroscopy, chromatography, and mass spectrometry, are employed to verify the identity, purity, and potency of the synthesized drugcompound. These tests ensure that the drug meets regulatory standards and requirements.6. Formulation and Drug Delivery:After the drug compound is synthesized and verified, formulation development takes place. Formulation scientists work to create the final dosage form, such as tablets, capsules, injections, or creams. They consider factors such as stability, solubility, and compatibility to ensure the drug's effectiveness upon administration to patients.7. Clinical Trials:Once the formulation is ready, clinical trials are conducted to evaluate the safety, efficacy, and side effects of the drug in humans. These trials follow strict protocols and involve multiple phases, including testing on healthy volunteers and patients. Clinical data obtained during these trials play a crucial role in evaluating the drug's therapeutic potential and obtaining regulatory approvals.8. Manufacturing and Quality Control:Upon successful clinical trials and regulatory approvals, the drug moves into large-scale manufacturing. Pharmaceutical companies utilize advanced manufacturing techniques toproduce the drug in bulk quantities while maintaining strict quality control measures. Quality control ensures that each batch of drug produced meets the required standards, efficacy, and safety.Conclusion:The synthesis of medicinal drugs involves a comprehensive and multidisciplinary approach, emphasizing innovation, precision, and scientific expertise. Through the stages ofdrug discovery, design, synthesis, formulation, clinical trials, and manufacturing, researchers and pharmaceutical companies strive to develop safe and effective medicationsfor improving human health. The continual advancement of medicinal drug synthesis techniques remains essential foraddressing the medical challenges of current and future generations.。
如何弘扬中医药文化英文读后感
如何弘扬中医药文化英文读后感Traditional Chinese medicine (TCM) is a time-honored medical system that has been practiced in China for thousands of years. It is a comprehensive approach to healthcare that encompasses various modalities, including herbal remedies, acupuncture, moxibustion, cupping, and Tai Chi. TCM's holistic perspective on health and well-being has gained increasing recognition and popularity worldwide. As a cultural heritage of China, it is crucial to promote the understanding and appreciation of TCM to preserve its rich tradition and unlock its potential in addressing modern healthcare challenges.One of the key aspects of promoting TCM culture is to raise awareness and educate the public about its fundamental principles and practices. TCM is based on the concept of balance and harmony within the human body, mind, and the natural environment. It emphasizes the interconnectedness of all aspects of an individual's well-being, and seeks to restore this balance through various therapeutic interventions. By understanding these core tenets, people can develop a deeper appreciation for the holistic approach of TCM and its potential to complement conventional Westernmedicine.Effective public education campaigns can be instrumental in disseminating information about TCM. These campaigns can include workshops, seminars, and public lectures that delve into the history, philosophy, and clinical applications of TCM. Healthcare professionals, traditional Chinese medicine practitioners, and experts in the field can serve as valuable resources and speakers, sharing their knowledge and personal experiences with the public. Additionally, the development of user-friendly educational materials, such as informative brochures, videos, and interactive websites, can help to make TCM more accessible and understandable to a wider audience.Another crucial aspect of promoting TCM culture is to foster the integration of traditional Chinese medicine into mainstream healthcare systems. This can involve collaborating with regulatory bodies and policymakers to establish appropriate guidelines, standards, and policies that recognize the legitimacy and safety of TCM practices. By integrating TCM into the broader healthcare landscape, patients can have greater access to this complementary approach, and healthcare providers can work in tandem to provide comprehensive, patient-centered care.Furthermore, the preservation and transmission of TCM knowledgeand practices are essential for the continued development and evolution of this medical tradition. This can be achieved through the support and funding of TCM research and education institutions, as well as the mentorship and training of the next generation of TCM practitioners. By investing in the training and development of qualified TCM professionals, the rich heritage of this ancient medical system can be safeguarded and passed on to future generations.Additionally, the promotion of TCM culture can involve the incorporation of traditional Chinese medicinal practices into various aspects of daily life. This can include the promotion of Tai Chi, Qigong, and other mind-body exercises that are rooted in TCM principles. The integration of TCM-inspired wellness practices, such as the use of herbal teas and essential oils, can also help to raise awareness and encourage the adoption of these traditional approaches to health and well-being.Moreover, the global recognition and appreciation of TCM can be enhanced through the active participation and representation of TCM practitioners and researchers in international healthcare forums and collaborations. By sharing their knowledge and experiences, and engaging in cross-cultural exchanges, TCM can gain greater visibility and credibility on the global stage. This can lead to increased opportunities for collaborative research, the exchange of best practices, and the integration of TCM into the broader healthcarelandscape worldwide.In conclusion, the promotion of traditional Chinese medicine culture is a multifaceted endeavor that requires a comprehensive and sustained effort. By raising public awareness, fostering the integration of TCM into mainstream healthcare, preserving and transmitting TCM knowledge, and engaging in global collaborations, we can work towards the goal of preserving and celebrating this invaluable cultural heritage. As we continue to explore the vast potential of TCM, we can unlock new avenues for holistic healthcare and contribute to the well-being of individuals and communities around the world.。
《中药学专业英语Traditional-Chinese-Medicines》
Recently, with the changes of human illness the people all over the world are making an appeal to go back to the nature, and getting to like natural resource. Meanwhile the influence of Chinese herbal medicines is over increasing in many countries.
et cetra = and so on
Compilation of Chinese Herbal Drugs 《全国中草药汇编》
An Encyclopedia of Chinese Materia Medica 《中药大辞典》
Chinese National Minorities Medicines, 《中国少数民族药物志》
Quality control is one of the important requirements for satisfactory curative effect of CMM. The scientific research groups, led by Prof. XU Guojun of our university and all, have done systematic studies on 105 different medicinal herbs. eg. Radix Codonopsis, Radix Ophiopogonis, Rhizoma Coptidis, tec., and proposed the criteria and methods of differentiating the Chinese medicinal herbs. It is significant for revising the national standards of some common-used Chinese materia medica.
香港浸会大学中医学硕士授课型研究生申请要求
香港浸会大学中医学硕士授课型研究生申请要求香港浸会大学简介学校名称香港浸会大学学校英文名称Hong Kong Baptist University学校位置中国 | 香港 | 九龙2020 QS 世界排名261香港浸会大学概述香港浸会大学(Hong Kong BaptistUniversity),简称“浸大”(HKBU),位于中国香港九龙,为中国香港特区政府全面资助的八所公立研究型综合大学之一。
其前身为香港浸信会联会于1956年创办的私立高等学府,致力提供全人教育。
现为京港大学联盟、粤港澳高校联盟、沪港大学联盟成员,获教育部列入国家重点高校名单。
浸大于2019年6月最新公布的QS世界大学排名中位列全球第261名;在2018泰晤士高等教育(THE)亚洲大学排名中,位列第55位。
在2019年THE世界大学影响力排名世界第60名,位居中国香港第二位。
中国香港浸会大学传理学院最负盛名,辖下新闻系在2011年经AsianCorrespondent新闻网评定为“亚洲学生心中的全球十大新闻学府”,和榜内的哥伦比亚大学新闻学院齐名,乃校内招生志愿的前三名。
在2018年计算机科学学科排名中,中国香港浸会大学理学院计算机科学系在人工智能领域学术排名世界第42位,位居香港第三位,在数据库领域排名世界第47名。
截止2019年7月,香港浸会大学计算机科学系人工智能学术领域排名世界第37位,位列香港第二位。
中医学硕士专业简介本课程的目的是培养和提高学生在临床实践中应用中医理论和方法的能力,以及中医的研究和发展。
通过实施该计划,学生掌握和掌握中医理论知识的能力将得到加强。
协调方法的教学各种中药专业知识和暴露在中药研究的最新发展,该项目将进一步提升学生的能力和标准在应用中医理论在临床实践和中药的研究和开发。
中医学硕士专业相关信息专业名称中医学硕士专业英文名称Master of Chinese Medicine (MCM)隶属学院中医学院学制1年语言要求中文GMAT/GRE 要求不要求2019 Fall 申请时间11月15日-2月28日2020 Fall 申请时间11月15日-20年2月29日学费(当地货币)130000中医学硕士课程内容序号课程中文名称课程英文名称1中医思维方法与方法学Thinking Approach andMethodology of Chinese Medicine 2中医研究方法与实务Research Methodology and Practices in Chinese Medicine3中药方剂的处方理论与实践Formulation Theories and Practices of Chinese Medicinal Formulae 4不同中医理论的临床应用Clinical Applications of the Different Theories of Chinese Medicine 5浓度的课程Studies and Applications of the Science of Seasonal Febrile Diseases 6温病学的研究和应用Theoretical and Clinical Studies onthe Miscellaneous Diseases of Internal Medicine7内科杂病的理论与临床研究Clinical Practice--Studies andApplications of Internal Chinese Medicine 8临床实践-内科学的研究与应用Dissertation序号课程中文名称课程英文名称9论文Studies and Applications of the Theory of Zhong Jing10仲景学说的研究与应用Examination and Diagnosis of Musculoskeletal Disorders11肌肉骨骼疾病的检查与诊断Clinical Acupuncture--Advanced Level 12临床Acupuncture-Advanced水平Clinical Practice--Studies and Applications of Acupuncture 13针灸临床实践研究与应用Dissertation14论文Advance in Acupuncture Research 15针灸研究进展Examination and Diagnosis of Musculoskeletal Disorders 16肌肉骨骼疾病的检查与诊断Clinical Practice--Studies and Applications of Orthopaedics, Traumatology and Tui Na 17临床实习-骨科、创伤学、推拿学的研究与应用Dissertation18论文Tui Na Therapy of Chinese Medicine 19中医推拿疗法Advanced Orthopaedics and Traumatology of Chinese Medicine20中医高级骨科及创伤学* 香港浸会大学中医学硕士研究生申请要求由Mastermate 收集并整理,如果发现疏漏,请以学校官网为准。
做新药研发管理你大概会觉得有用的几本入门书
做新药研发管理你大概会觉得有用的几本入门书药物的整个开发途径大约需要8-15年左右,这一段时间可以大致分成几个阶段,每个阶段的研究内容、所需知识都不尽相同。
如果对每一个阶段都希望进行管理,那么至少应当理解这些工作的意义和价值,管理的基础是至少部分地了解事物的本质,所以对于医药研发人员来说,需要一些必备的常识。
今天我们将首先划分药物研发的阶段,粗浅地讨论一下每一阶段所必备的知识,主要介绍一下获得这些知识的最快途径。
希望这些内容对于即将开始药物研发的新人能够提供一些帮助,尽量避免一些浪费时间的著作。
临床阶段部分可能要到下次再做分享。
红色字体强烈推荐。
药物研发的第一个主要阶段是化合物的发现与早期开发阶段。
这一阶段的主要目的是找出可能有效安全而且成药性较好的药物,药物化学家和生物学研究员是这一阶段的主要两类工作人员,工作的中心是药物化学家的药物分子设计。
本次推送的这一部分主要内容有两个:药物化学案例学习和生物学基础。
药物化学的案例学习药物化学在过去的30年内,受到法规环境、技术进步等多方面的影响,在药物设计上的进步可谓日新月异。
技术迭代在未完成产品开发就已经完成,使得技术进步未能见证产品优势。
药物化学家的工具也变得越来多丰富,无法判断一些药物的设计方法能否禁得住考验。
药物设计工具未经验证,药物化学团队需要一些案例指导。
在之前的推送里,我分享了药物化学的入门书籍,感兴趣的读者可以回翻到当期。
这类书的质量往往主要来源于药物发现团队是否讲述了足够多的内容,就是一般所谓的“干货”,另外选题与选材也比较重要。
由于缺少强有力的编辑团队,这类书的文笔参差不齐,推荐其中的《Accounts in Drug Discovery: Case Studies in Medicinal Chemistry》,与《Casestudies in modern drug discovery and development》。
国内去年的《明星药物》也可以读一读,但对于药物开发缺少实质帮助。
ICH-GCP中英文对照(完整)
ICH 三方协调指导原则E6 ICH GCP指导原则INTRODUCTION前言Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the participation of human subjects. Compliance with this standard provides public assurance that the rights, safety and well-being of trial subjects are protected, consistent with the principles that have their origin in the Declaration of Helsinki, and that the clinical trial data are credible.临床试验管理规范(GCP)是设计、实施、记录和报告设计人类对象参加的试验国际性伦理和科学质量标准。
遵循这一标准为保护对象的权利、安全性和健康,为与源于赫尔辛基宣言的原则保持一致以及临床试验数据的可信性提供了公众保证。
The objective of this ICH GCP Guideline is to provide a unified standard for the European Union (EU), Japan and the United States to facilitate the mutual acceptance of clinical data by the regulatory authorities in these jurisdictions.ICH-GCP指导原则的目的是为欧盟、日本和美国提供统一的标准,以促进这些管理当局在其权限内相互接受临床数据。
欧盟托管法案(EU)20171569临床试验药GMP原则和指南
欧盟托管法案(EU)20171569临床试验药GMP原则和指南COMMISSION DELEGATED REGULATION (EU) 2017/1569 of 23 May 2017supplementing Regulation (EU) No 536/2014 of the EuropeanParliament and of the Council by specifying principles of and guidelines forgood manufacturing practice for investigational medicinal products for humanuse and arrangements for inspections(Text with EEA relevance)欧盟托管法案(EU)2017/1569 2017年5月23日补充欧洲议会和欧盟委员会法规(EU)No.536/2014说明人用临床试验用药GMP原则和指南以及检查安排THEEUROPEAN COMMISSION,欧盟委员会Havingregard to the Treaty on the Functioning of the European Union,关于欧盟职能条约Havingregard to Regulation (EU) No 536/2014 of the European Parliament and of theCouncil of 16 April 2014 on clinical trials on medicinal products for humanuse, and repealing Directive 2001/20/EC[1],and in particular Article 63(1) thereof, 关于欧盟议会和委员会2014年4月16日关于人用临床试验用药的法规(EU)536/2014,以及即将废止的指令2001/20/EC,尤其是其中第63(1)条Whereas: 鉴于(1) The good manufacturing practice forinvestigational medicinal products for human use ensures that there isconsistency between batches of the same investigational medicinal product usedin the same or different clinical trials, andthat changes during thedevelopment of an investigational medicinal product are adequately documentedand justified. The manufacturing of investigational medicinal products presentsadditional challenges comparing to the manufacturing of authorised medicinal productsbecause there are no fixed routines, there is a variety of clinical trialdesigns and consequently packaging designs. Those challenges are due to theneed, often, of randomisation and to disguise the identity of theinvestigational medicinal products for the purpose of clinical trial(blinding). The toxicity, potency and sensitising potential of investigationalmedicinal products for human use may not be fully understood at the time of thetrial, and the need to minimise all risks of cross-contamination is thereforeof even greater importance than for authorised medicinal products. Because ofthis complexity, the manufacturing operations should be subject to a highlyeffective pharmaceutical quality system.人用临床试验用药GMP确保了用于相同或不同临床试验中的同种临床试验用药批次间的一致性,确保在临床试验用药研发期间的变更具有充分的记录和论证。
医药行业专业英语词汇
医药行业专业英语词汇(非常有用)FDA和EDQM术语: CLINICAL?TRIAL:临床试验? ANIMAL?TRIAL:动物试验? ACCELERATED?APPROVAL:加速批准? STANDARD?DRUG:标准药物? INVESTIGATOR:研究人员;调研人员PREPARING?AND?SUBMITTING:起草和申报? SUBMISSION:申报;递交? BENIFIT (S):受益? RISK(S):受害? DRUG?PRODUCT:药物产品? DRUG?SUBSTANCE:原料药? ESTABLISHED?NAME:确定的名称? GENERIC?NAME:非专利名称? PROPRIETARY?NAME:专有名称;? INN(INTERNATIONAL?NONPROPRIETARY?NAME):国际非专有名称? ADVERSE?EFFECT:副作用? ADVERSE?REACTION:不良反应? PROTOCOL:方案? ARCHIVAL?COPY:存档用副本? REVIEW?COPY:审查用副本? OFFICIAL?COMPENDIUM:法定药典(主要指USP、?NF).? USP (THE?UNITED?STATES?PHARMACOPEIA):美国药典NF(NATIONAL?FORMULARY):(美国)国家处方集? OFFICIAL=PHARMACOPEIAL=?COMPENDIAL:药典的;法定的;官方的? AGENCY:审理部门(指FDA)? IDENTITY:真伪;鉴别;特性? STRENGTH:规格;规格含量(每一剂量单位所含有效成分的量)? LABELED?AMOUNT:标示量? REGULATORY?SPECIFICATION:质量管理规格标准(NDA提供)? REGULATORY?METHODOLOGY:质量管理方法? REGULATORY?METHODS?VALIDATION:管理用分析方法的验证COS/CEP?欧洲药典符合性认证ICH(International?Conference?on?Harmonization?of?Technical?Requirements?for?Registration?of PharmaceuticalsforHumanUse)人用药物注册技术要求国际协调会议ICH文件分为质量、安全性、有效性和综合学科4类。
国际药物注册英语词汇
国际药物注册英语词汇互译FDA(foodand drug administration):(美国)食品药品监督管理局NDA(newdrug application):新药申请ANDA(abbreviated new drug application):简化新药申请EP(exportapplication):出口药申请(申请出口不被批准在美国销售的药品)treatment IND:研究中的新药用于治疗abbreviated(new)drug:简化申请的新药DMF(drugmaster file):药物主文件(持有者为谨慎起见而准备的保密资料,可以包括一个或多个人用药物在制备、加工、包装和贮存过程中所涉及的设备、生产过程或物品。
只有在DMF持有者或授权代表以授权书的形式授权给FDA,FDA在审查IND、NDA、ANDA时才能参考其内容)holder:DMF持有者CFR(codeof federalregulation):(美国)联邦法规PANEL:专家小组batch production:批量生产;分批生产batchproductionrecords:生产批号记录post orpre-market surveillance:销售前或销售后监督informed consent:知情同意(患者对治疗或受试者对医疗试验了解后表示同意接受治疗或试验)prescription drug:处方药OTC drug(over—the—counter drug):非处方药U.S. publichealth service:美国卫生福利部NIH(national institute of health):(美国)全国卫生研究所animaltrail:动物试验acceleratedapproval:加速批准standarddrug:标准药物investigator:研究人员;调研人员preparing andsubmitting:起草和申报submission:申报;递交benefit(s):受益risk(s):受害drug product:药物产品drugsubstance:原料药established name:确定的名称genericname:非专利名称proprietary name:专有名称;INN(international nonproprietaryname):国际非专有名称narrative summary: 记叙体概要adverse effect:副作用adversereaction:不良反应protocol:方案archivalcopy:存档用副本reviewcopy:审查用副本official compendium:法定药典(主要指USP、NF).USP(the united state pharmacopeia):美国药典(现已和NF合并一起出版)NF(nationalformulary):(美国)国家药品集official=pharmacopeial = compendial:药典的;法定的;官方的agency:审理部门(指FDA)sponsor:主办者(指负责并着手临床研究者)identity:真伪;鉴别;特性strength:规格;规格含量(每一剂量单位所含有效成分的量)labeledamount:标示量regulatory specification:质量管理规格标准(NDA提供)regulatory methodology:质量管理方法(FDA用于考核原料药或药物产品是否符合批准了的质量管理规格标准的整套步骤)regulatory methods validation:管理用分析方法的验证(FDA对NDA提供的方法进行验证)Dietary supplement:食用补充品ICH(InternationalConference on Harmonization of Tec hnical Requirements forRegistration ofPharmaceuticalsforHumanUse)人用药物注册技术要求国际协调会议ICH:Quality-质量Q1A(R2): Stability Testing of New Drug Substances andProducts(SecondRevision)新原料药和制剂的稳定性试验(第二版)Q1B: Photostability Testingof New Drug Substances and Products新原料药和制剂的光稳定性试验Q1C:StabilityTesting forNew Dosage Forms新制剂的稳定性试验Q1D: Bracketingand Matrixing Designs for Stability Testing ofDrugSubstances and DrugProducts原料药和制剂稳定性试验的交叉和矩阵设计Q1E: Evaluation of StabilityData对稳定性数据的评估处理Q1F:StabilityDataPackage forRegistrationApplications inClimaticZones III andIV在气候带III和IV,药物注册申请所提供的稳定性数据Q2A: Text on Validation of Analytical Procedures分析程序的验证Q2B: Validation of AnalyticalProcedures:Methodo logy分析程序的验证:方法学Q3A(R):Impuritiesin New DrugSubstances (RevisedG uideline)新原料药中的杂质(修订版)Q3B(R): Impurities in New Drug Products (Revised Guideline)新制剂中的杂质(修订版)Q3C: Impurities: Guideline forResidual Solvents杂质:残留溶剂指南Q3C(M):Impurities: Guideline for ResidualSolvents(Maintenance)杂质:残留溶剂指南(修改内容)Q4: Pharmacopoeias药典Q4A:Pharmacopoeial Harmonisation药典的协调Q4B:Regulatory Acceptance ofPharmacopoeial Interchangeability药典互替在法规上的可接受性Q5A: Viral Safety Evaluation ofBiotechnology ProductsDerived from CellLines of Human or AnimalOrigin来源于人或者动物细胞系的生物技术产品的病毒安全性评估Q5B: Quality of Biotechnological Products:Analysis of theExpressionConstruct in Cells Usedfor Production ofr-DNA Derived Protein Products生物技术产品的质量:源于重组DNA的蛋白质产品的生产中所用的细胞中的表达构建分析Q5C:Quality of Biotechnological Products: Stability TestingofBiotechnological/BiologicalProducts生物技术产品的质量:生物技术/生物产品的稳定性试验Q5D:Derivation and Characterisationof Cell Substrates Used forProductionofBiotechnological/BiologicalProducts用于生产生物技术/生物产品的细胞底物的起源和特征描述Q5E:Comparability of Biotechnological/Biological Pro ducts SubjecttoChanges in Their Manufacturing Process基于不同生产工艺的生物技术产品/生物产品的可比较性Q6: Specifications for New Drug Substances and Products新原料药和制剂的质量规格Q6A: Specifications:TestProceduresand AcceptanceCriteria for New DrugSubstances and New Drug Products: Chemical Substances质量规格:新原料药和新制剂的检验程序和可接收标准:化学物质Q6B: Specifications: TestProceduresand Acceptance Criteria forBiotechnological/BiologicalProducts质量规格:生物技术/生物产品的检验程序和可接收标准Q7:Good Manufacturing Practices forPharmaceutical Ingredients活性药物成份的GMPQ7A: Good ManufacturingPractice Guide forActivePharmaceuticalIngredients活性药物成份的GMP指南Q8:Pharmaceutical Development药物研发Q9: Quality Risk Management质量风险管理ICH:Safety-安全S1A:Guideline ontheNeed forCarcinogenicity Studies ofPharmaceuticals药物致癌性研究需要的指南S1B:Testing for Carcinogenicity of Pharmaceuticals药物致癌性的检验S1C:DoseSelection for Carcinogenicity Studies o fPharmaceuticals药物致癌性研究之剂量选择S1C(R):Addendum: Addition of a LimitDose andRelated Notes附录:极限剂量和有关注释的的补充S2A:Guidance on Specific Aspects of RegulatoryGenotoxicityTestsforPharmaceuticals受法规管辖的药物基因毒性检验的特定方面的指南S2B:Genotoxicity: A Standard Battery forGenotoxici ty Testing forPharmaceuticals基因毒性:药物基因毒性检验的标准S3A:Note for Guidanceon Toxicokinetics: The Assessment of SystemicExposureinToxicityStudies毒物代谢动力学指南的注释:毒性研究中的全身性暴露量的评估S3B:Pharmacokinetics: Guidancefor Repeated Dose Tissue D istributionStudies药物代谢动力学:重复剂量的组织分布研究指南S4: Single DoseToxicityTests单剂量毒性检验S4A: Duration of Chronic Toxicity Testing in Animals(Rodent andNon-Rodent Toxicity Testing)动物体内慢性毒性持续时间的检验(啮齿动物和非啮齿动物毒性检验)S5A: Detection of Toxicity to Reproduction forMedicinal Products药物对生殖发育的毒性的检验S5B(M):Maintenance ofthe ICH Guideline onToxicity t oMaleFertility:An Addendum tothe Guideline onDetection of Toxicity to ReproductionforMedicinal Products对男性生殖能力的毒性的指南的变动:药物对生殖发育的毒性的检验指南增加了一个附录S6:Preclinical Safety Evaluationof Biotechnology-Derived Pharmaceuticals生物技术生产的药物的临床前安全评价S7A:Safety Pharmacology Studiesfor Human Pharmaceuticals人用药的安全药理学研究S7B: The Nonclinical Evaluationof thePotentialfor D elayed VentricularRepolarization(QTInterval Prolongation) ByHuman Pharmaceuticals药物延迟心室复极化(QT间期)潜在作用的非临床评价S8:Immunotoxicology Studies forHuman Pharmaceut icals人用药免疫毒理学研究M3(M):Maintenanceof theICH Guideline on Non-Clinical Safety Studies fortheConductofHuman ClinicalTrials forPharmaceu ticals药物的对人临床试验的非临床安全研究指南的变动E-Efficacy(有效)E1: The Extent of Population Exposure toAssess Clinical Safety for DrugsIntended for Long-Term Treatment of Non-Life-Threatening Conditions对用于无生命危险情况下长期治疗的药物进行临床安全评估的族群暴露量范围E2A:Clinical SafetyData Management: Definitions and Standards forExpeditedReporting临床安全数据管理:速报制度的定义和标准E2B(R):Revisionof the E2B(M)ICHGuidelineon Clinical SafetyDataManagementDataElements forTransmissionof Individ ual Case SafetyReports个案安全报告送交的临床安全数据管理的数据要素指南(E2B(M))的修订版E2B (M):Maintenance of the Clinical SafetyDat aManagement including:Data ElementsforTransmissionof IndividualCase Safety Reports临床安全数据管理的变动包括:个案安全报告送交的数据要素E2B(M):Maintenance of theClinical Safety DataMana gement includingQuestions and Answers临床安全数据管理的变动,包括问答E2C: Clinical SafetyDataManagement:Periodic Sa fety UpdateReports forMarketed Drugs临床安全数据管理:已上市药品的周期性安全数据更新报告Addendum toE2C: Periodic Safety Update ReportsforMarketed DrugsE2C的附录:已上市药品的周期性安全数据更新报告E2D: Post-Approval Safety DataManagement:Defini tions andStandards forExpedited Reporting批准后的安全数据管理:速报制度的定义和标准E2E:PharmacovigilancePlanning药物警戒计划E3:Structure and ContentofClinical Study Reports临床研究报告的结构和内容E4: Dose-Response Information to Support Drug Registration支持药品注册的剂量-效应资料E5:Ethnic Factorsinthe AcceptabilityofForeign ClinicalData引入海外临床数据时要考虑的人种因素E6: GoodClinical Practice: Consolidated Guideline GCP:良好的临床规范:统一的指南E7: Studies inSupport of Special Populations: Geriatrics对特定族群的支持的研究:老人病学E8: General Considerations for Clinical Trials对临床试验的总的考虑E9: Statistical Principlesfor ClinicalTrials临床试验的统计原则E10: Choice of ControlGroup and Related Issuesin Clinical Trials临床试验中控制组和有关课题的选择E11: Clinical Investigationof MedicinalProducts in the PediatricPopulation小儿科药物的临床调查E12A:Principles forClinical Evaluation of New Antihyp ertensiveDrugs新抗高血压药物的临床评价原则E14: TheClinical EvaluationofQT/QTcInterval Prolongation andProarrhythmic Potential for Non-Antiarrhythmic Drugs非抗心率失常药物的QT/QTc间期和致心率失常潜在作用的临床评价MultidisciplinaryGuidelines多学科兼容的指南M1:MedicalTerminology医学术语M2: ElectronicStandards for Transmission of RegulatoryInformation(ESTRI)药政信息传递之电子标准M3:TimingofPre-clinicalStudies in Relationto Cli nical Trials(SeeSafetyTopics)有关临床试验的临床前研究的时间安排M4: The Common Technical Document (See CTD sectionforcompleteStatus oftheguidelines)通用技术文件(见有关CTD章节)M5:Data Elements and Standards for DrugDictionaries药物词典的数据要素和标准临床试验常用的英文缩略语TTP:time-to-progression疾病进展时间SAE: severity Adverse Event 严重不良事件AE:AdverseEvent 不良事件SOP:Standard OperatingProcedure标准操作规程CRF:Case Report form病例报告表DLT: 剂量限制毒性MTD: 最大耐受剂量KPS:Karnofsky Performance Status行为状态评分CR:completeresponse完全缓解PR: partial response部分缓解SD:病情稳定PD:progressive disease病情进展CTC: 常用药物毒性标准IEC: independent ethics committee独立伦理委员会IRB :institutional review board伦理委员会CRA: 临床研究助理CRO:Contract Research Organization 合同研究组织DFS: Disease Free Survival 无病生存期OS:(OverallSurvival)总生存时间IC: Informed consent知情同意ADR: Adverse Drug Reaction不良反应GAP:GoodAgriculturalPractice中药材种植管理规范GCP:Good Clinical Practice 药物临床试验质量管理规范GLP:Good Laboratory Practice 药品实验室管理规范GMP:Good Manufacturing Practice药品生产质量管理规范GSP:Good Supply Practice药品经营质量管理规范GUP:Good Use Practice 药品使用质量管理规范PI:Principal investigator 主要研究者CI:Co-inveatigator 合作研究者SI :Sub-investigator 助理研究者COI :Coordinating investigtor协调研究者DGMP:医疗器械生产质量管理规范ICF: Informed consentform知情同意书RCT : randomizedcontrolledtrial, 随机对照试验NRCCT:non-randomized concurrentcontrolledtrial, 非随机同期对照试验EBM:evidence-based medicine 循证医学RCD:randomized cross-over disgn随机交叉对照试验HCT: historial controltrial,历史对照研究RECIST: Response Evaluation CriteriaIn Solid Tumors.实体瘤疗效反应的评价标准QC:Quality Control质量控制UADR: UnexpectedAdverse Drug Reaction,非预期药物不良反应。
中药学(英语)笔记
第二节清热药(heat-clearing materia medica)1、Concept:Medicinals with the major function ofclearing interior heat are called, heat-clearing medicinals.2、Properties and efficacies:They are usually cold orcool in nature. Their efficacies are to clear heat, purge fire, relieve toxicity, and clear deficiency-heat. In addition, they can treat various heat diseases, high fever, heat dysentery, abscess, swelling, sores, toxin, as wellas various yin deficiency with internal heat syndrome.3、Classification: There are various causes, andpathogenesis, of the interior heat syndromes. Inaddition, there are different body constitutions anddifferent depths of heat, such as, in the qi or blood level, as well as, of excessive-heat and deficiency-heat. As a result, heat-clearing medicinals are sub-divided into five catergories as follows.(1)heat-clearing and fire-purging mediinal清热泻火药(2)heat-clearing and dampness-dryingmedicinal清热燥湿药(3)heat-clearing andblood-cooling medicinal清热凉血药(4)heat-clearing and toxicity-relieving medicinal清热解毒药(5)deficiency-heat-clering medicinal清虚热药(退骨蒸)A、heat-clearing and fire-purging mediinal清热泻火药1、石膏:It is the most significant medicinal to clear excess heat in qi level of the lung and the stomach.治疗气分肺胃实热的要药;stomach fire, toothache, headache, Xiaoke(diabetes)消渴证(葛根)2、知母:It is the most significant medicinal to purge excessive heat of the lung and stomach in qi level.治气分肺胃实热证(知母、石膏相须为用)3、栀子:⑴Medicinal properties: bitter and cold, relate to heart, lung and triple-energizer meridians.⑵Efficacies: purge fire, relieve agitation, clear fire, drain dampness, cool blood and relieve toxicity.⑶Clinical applications: warm disease and agitation(It is the most significant medicinal to treat agitation and uneasiness in warm disease.);damp-heat and jaundice; blood stranguria and astringent pain;B、heat-clearing and dampness-drying medicinal清热燥湿药苦参:kill worms and promote urination杀死体表寄生虫,利尿mutual antagonistic with 藜芦C、heat-clearing and toxicity-relieving medicinal清热解毒药1、金银花:(1)其特殊点:表里双解药物(2)efficacies: clear heat, relieve toxicity;disperse wind and discharge heat. 清热解毒,疏散风热(3)It is the most significant medicinal to treat internal abscess and external abscess, by itself or by pounding the fresh one for external application.内痈外痈之要药2、连翘:(1)表里双解药物,主归心经;(2)known as the saint medicinal for sores被称为“疮家圣药”(3)功效:clear heat and relieve toxicity; cure swelling; dissipate nodulation; disperse and relieve wind-heat清热解毒,消肿散结,疏散风热3、蒲公英:(1)It is the most significant medicinal to clear heat, relieve toxicity, cure abscess and dissipate nodulation, also is the most essential one to treat acute mastitis.治疗乳痈(乳腺炎)(2)功效:clear heat and relieve toxicity; cure swelling; dissipate nodulation; excrete dampness and remove stranguria.除湿通淋4、野菊花:clear heat and relieve toxicity清热解毒(利咽)5、鱼腥草:(1)relate to the lung meridian专入肺经;(2)It is the essential medicinal to treat lung abscess(治肺痈的要药);(3)功效:clear heat and relieve toxicity;cure abscess;expel pus;promote urination;treat stranguria 清肺热、清肺排脓6、白头翁:It is the most significant medicinal to treat dysentery,including tenesmus.治疗痢疾的要药,包括里急后重。
马兜铃酸肾毒性的研究进展
马兜铃酸肾毒性的研究进展彭金玲;边育红;王丽;李金奎【摘要】Aristolonic acid is a nitro phenanthrene organic acid compound found as a main component of Aristolochia, Guan mutong, Asanim, Aristolochia Fangchi and many other medicinal plants. Aristolochic acid is widely used in the pharmaceutical industry due to its anti infection, anti tumor, abortifacient and cellular immunity enhancing properties. Present uses of Aristolochic acid containing Chinese medicine are for the treatment of rheumatic and urinary system diseases. However, there have been increased reports on kidney damage as a result of using Aristolochic acid containing drugs, which, leads to increased research in the field. It is necessary and crucial to provide proper reference for safer clinical use of Chinese traditional medicines with Aristolochic acid components. This paper therefore focuses on the structure, toxicological effects and clinical applications of Aristolochic acid as well as its renal toxicological mechanisms. We therefore conclude that, due to the beneficial medicinal properties of Aristolochic acid, it is necessary to design a safer and effective pharmaceutical dosage formulation and strictly control drug dose and time as well as duration of drug use in order to reduce its toxic effect, thereby increasing its clinical ap-plication.%马兜铃酸(AA)为硝基菲类有机酸类化合物,是马兜铃、关木通、细辛、广防己等植物的主要成分.马兜铃酸药理作用广泛,有抗感染、抗癌、增强细胞免疫及终止妊娠等功能.目前,含有马兜铃酸的中药或中成药广泛应用于风湿及泌尿系统等多种疾病,由于服用含有马兜铃酸成分的中药而引起的肾脏损害报道日益增加,马兜铃酸肾毒性作用越来越受到人们的重视.本文总结了近年来马兜铃酸化学结构、毒理作用基础及临床研究,并对其肾毒理作用机制进行综述,使其为临床合理应用含有马兜铃酸的中药或中成药制剂提供参考.通过设计安全有效的药用剂型,严格控制用药剂量和时间,避免长期或大剂量服用,预防并减少毒性作用,将使该药在临床上得到更广泛应用.【期刊名称】《环球中医药》【年(卷),期】2013(006)001【总页数】5页(P60-64)【关键词】马兜铃酸;肾毒性;马兜铃酸肾病;发病机制【作者】彭金玲;边育红;王丽;李金奎【作者单位】063400,河北省唐山市丰润区第二人民医院计划免疫科;天津中医药大学中医学院免疫教研室;天津市传染病医院制剂科;新探健康发展研究中心控烟项目办公室【正文语种】中文【中图分类】R96马兜铃酸为硝基菲类有机酸,主要由马兜铃酸A、B、C、D、E等及其衍生物组成。
FDA临床试验常见词汇中译文对照
FDA临床试验常见词汇中译文对照Aaction letter 决定通知active comparator 活性药物对照组active control = AC 阳性对照,活性对照active ingredient 有效成分Active Substance Master File (ASMF) 欧洲药物主文件acute myocardial infarction 急性心肌梗死acute tibial fractures 急性胫骨骨折adalimumab (Humira) 阿达木单抗adaptive design 自适应设计adaptive randomization 自适应随机ADE = adverse drug event 药物不良事件Adenoviral Vectors 腺病毒载体adequate and well-controlled studies 充分严格的对照研究ADHD = Attention-deficit hyperactivity disorder注意力缺陷多动障碍; 注意力不足过动症; 多动症adhesion barrier product 防黏著产品adjuvant 助剂; 佐剂auxiliary;adjuvant therapy 佐药疗法,辅助疗法ADL = activities of daily living 日常生活活动能力ADME = absorption, distribution, metabolism, and excretion(药物)吸收、分配、代谢和排除ADR = adverse drug reaction 药物不良反应adrenal cortex 肾上腺皮质adrenal cortical hormone 肾上腺皮质激素adrenal gland 肾上腺adrenaline 肾上腺素adulterated devices 掺假器械adverse drug reaction = ADR药物不良反应adverse effect 副作用adverse event = AE 不良事件adverse medical events 不良医学事件adverse reaction (adverse event) 药物不良反应advisory 提醒advocacy and support groups 倡导和支持团体AE = adverse event 不良事件AERS = Adverse Event Reporting System 不良事件报告系统BBIMO Bioresearch Monitoring Program 生物研究监测bioavailability (F) 生物利用度biochemical drugs 生化药品biocides 生物杀灭剂; 杀生物剂biocompatibility 生物相容性biodegradable 生物分解bio-engineered, transgenic food 转基因食物bioequivalence; bioequivalent 生物等效应biofilm 细菌薄膜, 生物膜biologic 生物制品biological response modifiers BRM 生物应答调节剂biological therapeutic agents 生物治疗药剂biomarker 生物标志物biometrics 生物统计; 生物识别技术bion stimulator 生物体刺激器bionic knee 仿生膝关节biopharma: biopharmaceutical products 生物药物产品bipolar 双相燥郁症birth defect 出生缺陷, 新生儿缺陷, 先天缺陷BLA = biologic license application 生物制品许可申请blank control 空白对照blend uniformity analysis 混合均匀度分析blind 盲法blind codes 编制盲底blind review 盲态审核blinding method 盲法blinding/ masking 盲法,设盲blister packaging 泡罩包装; 水泡眼block 分段;层block size 每段的长度blocked randomization 区组随机Ccase history 病历case record form = CRF病例报告表/病例记录表case report form 病例报告表cash curve 现金曲线cash trap 现金陷阱; 现金套牢categorical variable 分类变量CLIA Clinical Laboratory Improvement Amendments临床实验室改进修订案clinical (human) data 临床数据clinical endpoint临床终点clinical equivalence 临床等效应clinical hold 临床试验暂停通知clinical investigator 临床研究者Clinical Pharmacists 临床药师Clinical Research Coordinator = CRC临床研究协调者clinical study 临床研究Clinical Study Application = CSA临床研究申请clinical study report 临床试验的总结报告clinical trial 临床试验clinical trial application = CTA 临床试验申请clinical trial exemption = CTX 临床试验免责clinical trial protocol = CTP 临床试验方案Clinical Trial Report = CTR临床试验报告clinically significant results 有临床意义cohort 队列cohort studies 队列研究co-investigator = CI合作研究者comparison 对照Compassionate Use 体恤使用competitive labeling 优越标签Complementary And Alternative Therapy 补充性和非传统治疗Complete response 完全有效compliance 遵守;对遵守法规情况的监管composite variable 复合变量Compression Test 压缩试验computer-assisted trial design= CATD计算机辅助试验设计Con Meds = concomitant medications 联合用药confidence interval 可信区间confidence level 置信水平Confidentiality Regarding Trial Participants 为试验参与者保密control对照control group 对照组controlled clinical trials 临床对照实验Controlled Trials 对照试验Critical Path 关键路径CRM = continual reassessment method 连续重新评估方法crossover design 交叉设计cross-over study 交叉研究crossover therapy 交叉治疗CRF = case report form 病例报告表dosage form 剂型dosage regimen 给药方案dose-ranging study 剂量范围研究dose-reaction relation 剂量-反应关系dose-related adverse reactions 剂量相关的不良反应double blinding 双盲double dummy 双模拟double dummy 双模拟double dummy technique 双盲双模拟技术double-blind study 双盲研究Double-Masked Study 双盲研究DRGs = Diagnosis Related Group System 疾病诊断相关分组drop out 脱落drop test 落震试验;跌落试验drug eluting coronary stents 药物洗脱支架drug product 药物产品drug substance 原料药drug-drug interaction56 药物-药物相互作用drug-food interaction 药物-食物的相互作用EEPS = Electronic Entry Processing System 电子录入处理系统effectiveness 疗效efficacy 有效性测定efficacy (Of a drug or treatment) 药效;药品疗效EEMEA = European Medical Evaluation Agency; European Agency for the Evaluation of Medicinal Products; European Medicines Agency 药物评价机构; 欧洲医药品管理局emergency envelope 应急信件Empiric Bayesian Multiple Gamma-Poisson Shrinker经验性贝氏法(伽玛泊松分布缩检法)empirical 经验性endpoint 终点endpoint criteria 终点指标factorial design 析因设计factorial trial 析因试验failure 无效,失败Fair Packaging and Labeling Act (1966) 公平包装和标签法False Claims Act 防制不实请求法false therapeutic claims 错误的疗效声明full analysis set 全分析集full factorial design 全因子试验法Iinclusion criteria 入选标准inclusion/exclusion criteria 入选/排除标准incremental exposure 食品中递增摄入量incubation period/latency period 潜伏期IND = Investigational New Drug 临床研究新药INDA = investigational new drug application NDA前申报阶段indemnity insurance 赔偿保险Independent Data Monitoring = IDM独立数据监察Independent Data Monitoring Committee = IDMC独立数据监察委员会independent ethics committee = IEC 独立伦理委员会indications 适应症investigational new drug = IND 临床研究新药investigational product 试验药物investigator 调研人员investigator's brochure = IB 研究者手册Mmasked 设盲mean absorption time = MAT(药物在体内的)平均吸收时间mean disintegration time = MDIT(药物在体内的)平均崩解时间Mean Dissolution Time = MDT (药物在体内的)平均释放时间Mean Residence Time = MRT(药物在体内的)平均滞留时间medical governance 医药治理Medicare 老年医疗保险制度;联邦老年医保medication guides (for patients) 用药指南Medicines Control Agency = MCA英国药品监督局Misbranding 错误标签; 冒牌Miscoding 编码错误missing value 缺失值mixed effect model 混合效应模式MLD = minimal lethal dose 最小致死剂量MoA = Mechanism of Action 作用机制;作用机理monitor 监查员monitoring plan监查计划monitoring report 监查报告MR = moderate response 好转MRA = Agreement on Mutual Recognition 相互承认协定MTD = maximal tolerance dose 最大耐受剂量multicenter trial 多中心试验multi-drug resistance 多药物抗药性multiple arm trials 多治疗组的试验mutual recognition procedure (EU) 相互承认程序OOS = Overall survival 总生存率Pparallel group design 平行组设计parameter estimation 参数估计parametric release 参数放行parametric statistics 参数统计方法patient file 病人档案patient global; pt global 病人总体评价patient history 病历per protocol ( PP) analysis 符合方案分析PFS = progression-free survival 无疾病进展存活率PGE = patient global evaluation 病人总体评价PHA = preliminary hazards analysis 预先危险分析pharmaceutical equivalence 药剂等效性pharmaceutics药剂学pharmacodynamics=PD 药物效应动力学; 简称药效学pharmacoepidemiology 药物流行病学pharmacokinetics = PK 药代动力学; 简称药动学pharmacology 药理学Pharmacovigilance105 药物警戒pharmacy 配药学PharMetrics claims database 索赔数据库PhRMA = Pharmaceutical Research and Manufacturers of America美国药物研究与生产商协会PIC=Pharmaceutical Inspection Convention 药品检查协定PIC/S Pharmaceutical Inspection Cooperation Scheme 药物检查合作计划pipeline assets 开发中产品PK = pharmacokinetics 药物代谢动力学; 药动学,药代动力学placebo 安慰剂placebo control 安慰剂对照placebo controlled study 安慰剂对照研究placebo effect 安慰剂效应PMA = premarket approval 上市前许可; 销售前批准PMCs = post marketing commitments 承诺药品上市后的继续研究PMDRA = Post Marketing Drug Risk Assessment 上市后药品风险评估(办公室) PMHx = Past Medical History 既往病史PMN = Premarket Notification 销售前通知PMS = Premenstrual syndrome 经前综合症POC (Proof-of-concept) Clinical Trials 概念证明POC = point-of-care testing 床旁分析polytomies 多分类pooled analysis = PA 荟萃分析postmarket surveillance 上市后监督post-marketing surveillance; postmarket safety surveillance 销售(上市)后监督power 把握度; 检验效能Pp = Process Performance 工序绩效Ppk = Process Performance Index 工序绩效指数precautions 慎用;注意事项precision 精密度preclinical (animal) data 临床前(动物实验)数据preclinical study 临床前研究predicate device = legally marketed device that is not subject to Premarket Approval (PMA)和已合法在市场上销售的且不需要做PMA“销售前批准”的Pre-market Approval (Application) = PMA上市前许可(申请)premarket notification 上市前通知pre-marketing surveillance 销售(上市)前监督preparing and submitting 起草和申报prescription drug 处方药preservation 保藏prevalence 患病率prevention trials预防试验primary (coronary) event 原位病变primary endpoint 主要终点primary mode of action = PMOA 首要作用模式primary variable 主要变量principal investigator = PI主要研究者Principles of Qualification 确认(验证)原则process controls 工艺控制process validation 工艺验证product codes 产品的号码product differentiation 产品差异化,产品特色化product license = PL 产品许可证product life cycle (PLC) 产品生命周期prognosis 预后progression-free survival = PFS 无进展生存progressive Disease PD 病情进展proof of principle study 原理循证研究propensity score 倾向性评分protocol 试验方案; 方案protocol amendment 方案补正prototype design 原型设计protozoa 原生动物门proven acceptable Range = PAR 确定可接受范围PTC = Product Technical Complaints 药品技术投诉Qqualification system for licensed pharmacist 执业药师资格准入制度qualified health claims 有保留的健康宣称Qualified Person = QP 受权人quality assurance = QA质量保证quality assurance unit = QAU质量保证部门quality control = QC 质量控制quality management systems 质量管理体系quality of life trials or supportive care trials 生存质量试验quality risk management = QRM 质量风险管理quantitative risk assessment 量化风险评估Rrandomization 随机化randomized trial 随机化试验randomized, double blinded clinical trial 随机双盲对照研究range check 范围检查rating scale 量表RCT = randomized clinical trials 随机临床试验RCT = randomized controlled trial 随机对照试验RDE: remote data entry 远距数据输入ready-to-eat foods 即食食品reagents 试剂recall 召回; 强制回收RECIST = Response Evaluation Criteria in Solid Tumors 实体瘤的疗效评价标准reconditioning 整改; 货物重整理;货物重包装recycled plastics 可循环利用塑料制品reference product 参比制剂reference samples 标准样品regulatory methodology 质量管理方法regulatory methods validation 管理用分析方法的验证(FDA对NDA提供的方法进行验证)regulatory specification 质量管理规格标准(NDA提供)rejection 排异remote monitoring system 远程监测系统; 远程监控REMS = Risk Evaluation and Mitigation Strategies 风险评估和减缓战略risk 受害risk assessment (risk analysis + risk evaluation) 风险评估,论证risk classification 风险分类;Risk Communications Advisory Committee 风险交流咨询委员会risk evaluation (part of risk assessment) 风险评价risk/ benefit analysis 风险-获益分析risk-benefit ratio 效益/风险比route of administration 给药途径royalties 专利使用费RPN = Risk Priority Number 风险优先指数RR = Response rate 缓解率RSD = (intra-day and inter-day) relative standard deviations (日内和日间) 相对标准差Ssafety advisory 安全建议safety evaluation 安全性评价safety evaluators 安全性评估人员safety set 安全性评价的数据集screening trials 筛选性试验SD = standard deviation 标准(偏)差SE = substantial equivalence 实质上的等同Seal Strength Test 密封强度试验sequence 试验次序SFDA 129= State Food And Drug Administration 国家食品药品监督管理局SG & A= Sales, General and Administration 销售、管理和一般费用shaft 传动轴SHEA = Society for Healthcare Epidemiology of America 美国医院流行病学学会sheaths 护套shelf life 保存期限; 保质期SIC codes = Standard Industrial Classification codes 标准产业分类代码side effects 副作用significance level 显著性水平Significant Risk (SR) 显著的危险性simple randomization 简单随机simulation model 仿真模型single blinding单盲single-blind study 单盲研究single-masked study 单盲研究site assessment = SA现场评估site audit 试验机构稽查SMDA = Safe Medical Devices Act of 1990 1990年安全医疗器械法SMF = Site Master File 生产场所主文件sNDA = supplemental NDA 疗效补充新药上市申请sponsor-investigator = SI 申办研究者spontaneous reports; voluntary reports 药品不良反应自愿报告SPS = Agreement on the Application Of Sanitary and Phytosanitary Measures卫生与植物卫生措施实施协议;简称SPS协议SSI = surgical site infection 手术部位感染SSOPs = Sanitation Standard Operating Procedures 卫生标准操作程序standard curve 标准曲线standard deviation 标准偏差standard drug 标准药物standard operating procedure = SOP 标准操作规程standard treatment 标准治疗Standards Of Care131 医护标准State Food and Drug Administration = SFDA国家食品药品监督管理局statistic 统计量statistical analysis plan = SAP 统计分析计划statistical model 统计模型statistical significance 统计学意义statistical tables 统计分析表Statisticians in the Pharmaceutical Industry = PSI制药业统计学家协会steady-state Area Under the Curve = AUCss稳态药时曲线下面积/稳态血药浓度-时间曲线下面积stratified 分层study audit 研究稽查study endpoint 研究终点Study Personnel List = SPL研究人员名单study site研究中心study type 研究类型subchronic toxicity studies 亚慢性毒性研究subgroup 亚组sub-investigator 助理研究者subject 受试者subject diary = SD 受试者日记subject enrollment 受试者入选subject enrollment log = SEL受试者入选表Subject Identification Code List = SIC受试者识别代码表subject recruitment 受试者招募subject screening log = SSL受试者筛选表submission 申报;递交subspecialties, internal medicine 亚专科,内科substantial equivalence to legally marketed (predicate) device 和已合法在市场上销售的且不需要做PMA“销售前批准”的相似产品有实质上的等同Ttrain-the-trainer program 培训者培训计划treatment group 试验组treatment IND 治疗性试验性新药申请treatment trials 治疗性试验trial error 试验误差trial initial meeting 试验启动会议trial master file 试验总档案trial objective 试验目的trial site 试验场所TRICARE 军队医疗系统triple blinding 三盲two one-side test 双单侧检验UAE = unexpected adverse event 预料外不良事件unblinding 破盲;揭盲under reporting bias 少报偏差unexplained syncope 不明原因晕厥unresectable 不能手术切除variability 变异variable 变量WHO International Collaborating Center for Drug Monitoring(世界卫生组织)国际药物监测合作中心WHO International Conference of Drug Regulatory Authorities= WHO-ICDRAWHO国际药品管理当局会议WHO Programme for International Drug Monitoring = PIDMWHO 国际药物监测合作计划。
倍他米松水杨酸软膏说明书信息(英国上市)
Summary of Product Characteristics last updated on the eMC: 14/04/2011Diprosalic OintmentHertford Road, Hoddesdon, Hertfordshire, EN11 9BU1. NAME OF THE MEDICINAL PRODUCT2. QUALITATIVE AND QUANTITATIVE COMPOSITION3. PHARMACEUTICAL FORM4. CLINICAL PARTICULARS4.1 Therapeutic indications4.2 Posology and method of administrationDiprosalic OintmentBetamethasone Dipropionate 0.064% w/w*(* equivalent to 0.05% Betamethasone)Salicylic Acid 3.00% w/wOintmentBetamethasone Dipropionate is a synthetic fluorinated corticosteroid. It is active topically and produces a rapid and sustained response in those inflammatory dermatoses that are normally responsive to topicalcorticosteroid therapy, and it is also effective in the less responsive conditions, such as psoriasis of the scalp, chronic plaque psoriasis of the hands and feet, but excluding widespread plaque psoriasis.Topical salicylic acid softens keratin, loosens cornified epithelium and desquamates the epidermis.Diprosalic presentations are therefore indicated for the treatment of hyperkeratotic and dry corticosteroid-responsive dermatoses where the cornified epithelium may resist penetration of the steroid. The salicylic acid constituent of Diprosalic preparations, as a result of its descaling action, allows access of the dermis more rapidly than by applying steroid alone. Adults :Once to twice daily. In most cases a thin film should be applied to cover the affected area twice daily. For some patients adequate maintenance therapy may be achieved with less frequent application.It is recommended that Diprosalic preparations are prescribed for two weeks, and that treatment is reviewed at that time. The maximum weekly dose should not exceed 60g. Merck Sharp & Dohme Limited Telephone: +44 (0)1992 467 272Fax: +44 (0)1992 479 292Medical Information e-mail: medicalinformationuk@Before you contact this company: often several companieswill market medicines with the same active ingredient. Pleasecheck that this is the correct company before contactingthem. Why?Dosage in children should be limited to 5 days.4.3 ContraindicationsRosacea, acne, perioral dermatitis, perianal and genital pruritus. Hypersensitivity to any of the ingredients of the Diprosalic presentations contra-indicates their use as does tuberculous and most viral lesions of the skin, particularly herpes simplex, vacinia, varicella. Diprosalic should not be used in napkin eruptions, fungal or bacterial skin infections without suitable concomitant anti-infective therapy.4.4 Special warnings and precautions for useOcclusion must not be used, since under these circumstances the keratolytic action of salicylic acid may lead to enhanced absorption of the steroid.Local and systemic toxicity is common, especially following long continuous use on large areas of damaged skin, in flexures or with polythene occlusion. If used in children or on the face courses should be limited to 5 days. Long term continuous therapy should be avoided in all patients irrespective of age.Topical corticosteroids may be hazardous in psoriasis for a number of reasons, including rebound relapses following development of tolerance, risk of generalised pustular psoriasis and local systemic toxicity due to impaired barrier function of the skin. Careful patient supervision is important.It is dangerous if Diprosalic presentations come into contact with the eyes. Avoid contact with the eyes and mucous membranes.The systemic absorption of betamethasone dipropionate and salicylic acid may be increased if extensive body surface areas or skin folds are treated for prolonged periods or with excessive amounts of steroids. Suitable precautions should be taken in these circumstances, particularly with infants and children.If irritation or sensitization develops with the use of Diprosalic Ointment and Lotion, treatment should be discontinued.Any side effects that are reported following systemic use of corticosteroids, including adrenal suppression, may also occur with topical corticosteroids, especially in infants and children.If excessive dryness or increased skin irritation develops, discontinue use of this preparation.Peadiatric Use: Peadiatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hypothalamic-pituary-adrenal (HPA) axis suppression and to exogenous corticosteroid effects than mature patients because of greater absorption due to a large skin surface area to body weight ratio.HPA axis suppression, Cushing's syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels and absence of response to ACTH stimulation.Manifestations of intracranial hypertension include a bulging fontanelle, headaches and bilateral papilledema.4.5 Interaction with other medicinal products and other forms of interactionNone stated4.6 Pregnancy and lactationSince safety of topical corticosteroid use in pregnant women has not been established, drugs of this class should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus. Drugs of this class should not be used extensively in large amounts or for prolonged periods of time in pregnant patients.Since it is not known whether topical administration of corticosteroids can result in sufficient systemicabsorption to produce detectable quantities in breast milk, a decision should be made to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.4.7 Effects on ability to drive and use machines4.8 Undesirable effectsDiprosalic skin preparations are generally well tolerated and side-effects are rare.Continuous application without interruption may result in local atrophy of the skin, striae and superficial vascular dilation, particularly on the face.Adverse reactions that have been reported with the use of topical corticosteroids include: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis and allergic contact dermatitis.The following may occur more frequently with the use of occlusive dressings: maceration of the skin,secondary infection, skin atrophy, striae and miliaria.In addition, prolonged use of salicylic acid preparations may cause dermatitis.4.9 OverdoseExcessive prolonged use of topical corticosteroids can suppress pituitary-adrenal functions resulting insecondary adrenal insufficiency, and produce manifestations of hypercorticism, including Cushing's disease.Treatment: Appropriate symptomatic treatment is indicated. Acute hypercorticoid symptoms are usually reversible. Treat electrolyte imbalance, if necessary. In case of chronic toxicity, slow withdrawal ofcorticosteroids is advised.With topical preparations containing salicylic acid excessive prolonged use may result in symptoms ofsalicyclism. Treatment is symptomatic. Measures should be taken to rid the body rapidly of salicylate.Adminster oral sodium bicarbonate to alkalinize the urine and force diuresis.The steroid content of each tube is so low as to have little or no toxic effect in the unlikely event of accidental oral ingestion.5. PHARMACOLOGICAL PROPERTIES5.1 Pharmacodynamic propertiesDiprosalic preparations contain the dipropionate ester of betamethasone which is a glucocorticoid exhibiting the general properties of corticosteroids, and salicylic acid which has keratolytic properties.Salicylic acid is applied topically in the treatment of hyperkeratotic and scaling conditions where its keratolytic action facilitates penetration of the corticosteroid.In pharmacological doses, corticosteroids are used primarily for their anti-inflammatory and/or immune suppressive effects.Topical corticosteroids such as betamethasone dipropionate are effective in the treatment of a range of dermatoses because of their anti-inflammatory, anti-pruritic and vasoconstrictive actions. However, while the physiologic, pharmacologic and clinical effects of the corticosteroids are well known, the exact mechanisms of their action in each disease are uncertain.5.2 Pharmacokinetic propertiesSalicylic acid exerts only local action after topical application.The extent of percutaneous absorption of topical corticosteroids is determined by many factors including vehicle, integrity of the epidermal barrier and the use of occlusive dressings.Topical corticosteroids can be absorbed through intact, normal skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption.Once absorbed through the skin, topical corticosteroids enter pharmacokinetic pathways similar tosystemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees, are metabolised primarily in the liver and excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted in the bile.5.3 Preclinical safety dataThere are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.6. PHARMACEUTICAL PARTICULARS6.1 List of excipientsLiquid ParaffinWhite Soft Paraffin6.2 IncompatibilitiesNone Stated.6.3 Shelf life60 months6.4 Special precautions for storageDo not store above 25°C.6.5 Nature and contents of container15, 30 or 100gm expoxy-lined aluminium tubes with plastic caps.6.6 Special precautions for disposal and other handlingNot applicable7. MARKETING AUTHORISATION HOLDERMerck Sharp & Dohme LimitedHertford RoadHoddesdonHertfordshireEN11 9BUUK8. MARKETING AUTHORISATION NUMBER(S)PL 00025/05709. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION10th June 1986 / 25th July 199710. DATE OF REVISION OF THE TEXT21 March 2011Prescription Only Medicine© Merck Sharp & Dohme Limited 2011. All rights reserved. DIPROSALIC Ointment/UK/04-11/06。
创新药物临床试验中临床药理学研究的一般考虑
发布日期20140404栏目化药药物评价>>综合评价标题创新药物临床试验中临床药理学研究的一般考虑作者张学辉卓宏王涛鲁爽部门化药临床二部正文内容临床药理学是研究药物与人体相互作用规律的一门学科,它以药理学和临床医学为基础,阐述药物代谢动力学(简称药动学)、药物效应动力学(简称药效学)、不良反应的性质和机制及药物相互作用规律等。
从药物的生命周期看,临床药理学贯穿于药物临床试验、药物上市后研究与评价、药物临床治疗等阶段。
从药物临床试验看,临床药理学研究是其重要组成部分,主要在I期进行,其他三期(II~IV期)中也进行很多此类研究[1]。
为理性开展和评价临床药理学研究,本文在综合国内外临床药理研究相关指导原则基础上,对创新药物临床试验中临床药理学研究相关内容进行了系统阐述,以期在监管机构、业界和学术界展开讨论并形成共识,为药物临床研发与评价提供临床药理学决策依据。
一、药物临床试验中临床药理学研究的基本任务药物临床试验中临床药理学研究的基本任务是,要应用符合法律和伦理要求的当前最佳科技手段,提供临床药理学和生物药剂学数据,支持药物在新药临床试验申请(IND)和新药上市申请(NDA)过程中安全性和有效性的评估。
研究内容包括药物对人体的效应(药效学和不良反应)、人体对药物的处置(药动学)、剂量-暴露量-效应关系、药物相互作用、特殊人群的临床药理学、药物基因组学、定量药理学与统计分析等。
在不同临床试验阶段,临床药理学的研究任务和内容又各不相同。
为便于叙述,本文将临床试验分为早期临床试验阶段(I~IIa)和后期临床试验阶段(IIb~IV)。
二、早期药物临床试验中临床药理学研究早期(I~IIa)临床试验,几乎全部是临床药理学相关研究工作。
早期临床试验,承接药物非临床研究(主要指毒理学、药代动力学试验、药效动力学试验)的结果,转化到人体中开展耐受性试验、药代动力学试验和药效动力学试验。
其主要目的在于:1)对非临床研究的动物试验结果进行概念验证(Proof of Concept),并分析人和动物的种属差异;2)初步评估药物在人体上的安全性和有效性,做出是否继续研发的决策;3)若继续研发,为后期临床试验优化出能够平衡获益和风险的剂量和给药方案。
医疗药品FDA医药英文词汇
baseline basiliximab(tradenameSimulect) batchproduction batchrelease Baycol(cerivastatinsodium) BayerScheringPharma BCGBostonConsultingGroup benchtest benefit benzodiazepine17 benzoicacid BestPharmaceuticalsforChildrenAct2002 beta-blocker Bextra(valdecoxib) BfARM=BundesinstitutfürArzneimittelundMedizinprodukte BHC=BayerHealthCare bias19 bicohortstudy bilirubin BIMOBioresearchMonitoringProgram bioavailability(F)20 biochemicaldrugs biocides
Alzheimer’sDisease aminoacidsequence aminoglycosideantibiotics amphetamines amyotrophiclateralsclerosis=ALS analysisofcovariance(ANCOVA)10 analysissets analyte anaphylaxis ANDA=abbreviatednewdrugapplication anginapectoris angioplastyballoons animaltrial anotia antibioticprophylaxis antibioticresistance anti-inflammatoryagents anti-metabolites antimicrobialresistance anti-nutrients antipyretic,analgesicsandanti-inflammatorydrugs anti-TNFagent;TNFblockerdrugs anti-TNFtherapy
ICH指导原则文件目录(中英文)
ICH指导原则文件目录(中英文)人用药品注册技术要求国际协调会(ICH)文件目录ICH的论题主要分为四类,因此ICH根据论题的类别不同而进行相应的编码分类:1. “Q”类论题:Q代表QUALITY,指那些与化工和医药,质量保证方面的相关的论题。
Q1/Q2...Q10都属于这类。
2. “S”类论题:S代表SAFETY,指那些与实验室和动物实验,临床前研究方面的相关的论题。
3. “E”类论题:E代表EFFICACY,指那些与人类临床研究相关的课题。
4. “M”类论题:M代表MULTIDISCIPLINARY, 指那些不可单独划入以上三个分类的交叉涉及的论题。
同时M又细分为5个小类:M1: 常用医学名词(Med DRA)M2: 药政信息传递之电子标准M3: 与临床试验相关的临床前研究时间的安排M4: 常规技术文件(CTD)M5: 药物词典的数据要素和标准一、ICH. 质量部分(Quality)稳定性1.Quality质量2.Q1: Stability稳定性3.Q1A(R2): Stability Testing of New Drug Substances and Products 新原料药和制剂的稳定性试验4.Q1B: Photostability Testing of New Drug Substances and Products 新原料药和制剂的光稳定性试验5.Q1C: Stability Testing for New Dosage Forms 新剂型的稳定性试验6.Q1D: Bracketing and Matrixing Designs for Stability Testing of Drug Substances and Drug Products原料药和制剂稳定性试验的交叉和矩阵设计 Q1E: Evaluation of Stability Data 稳定性数据的评估7.Q1F: Stability Data Package for Registration Applications in Climatic Zones III andIV在气候带III和IV,药物注册申请所提供的稳定性数据8.Q2: Analytical Validation分析验证9.Q2(R1): Validation of Analytical Procedures: Text and Methodology分析程序的验证:正文及方法论10.Q3: Impurities 杂质11.Q3A(R2): Impurities in New Drug Substances 新原料药中的杂质12.Q3B(R2): Impurities in New Drug Products (Revised Guideline) 新制剂中的杂质13.Q3C(R3): Impurities: Guideline for Residual Solvents 杂质:残留溶剂指南Impurities: Guideline for Residual Solvents (Maintenance) 杂质:残留溶剂指南(保留)PDE for Tetrahydrofuran (in Q3C(R3)) 四氢呋喃的日允许接触剂量PDE for N-Methylpyrrolidone (in Q3C(R3)) N-甲基吡咯烷酮的日允许接触剂量14.Q4: Pharmacopoeias药典15.Q4A: Pharmacopoeial Harmonisation 药典的协调16.Q4B: Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions药典内容的评估及推荐为用于ICH地区17.Q4B Annex1 Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regionson Residue on Ignition/Sulphated Ash General Chapter附录1 药典内容的评估及推荐为用于ICH地区关于灼烧残渣/灰分常规篇18.Q4B Annex2 Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regionson Test for Extractable Volume of Parenteral Preparations General Chapter附录2 药典内容的评估及推荐为用于ICH地区关于注射剂可提取容量测试常规篇19.Q4B Annex3 Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regionson Test for Particulate Contamination: Sub-Visible Particles General Chapter附录3 药典内容的评估及推荐为用于ICH地区关于颗粒污染物测试:不溶性微粒常规篇20.Q5: Quality of Biotechnological Products 生物技术制品质量21.Q5A(R1): Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin来源于人或者动物细胞系的生物技术产品的病毒安全性评估22.Q5B: Quality of Biotechnological Products: Analysis of the Expression Construct in Cells Used for Production of r-DNA Derived ProteinProducts生物技术产品的质量:源于重组DNA的蛋白质产品的生产中所用的细胞中的表达构建分析23.Q5C: Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products生物技术产品的质量:生物技术/生物产品的稳定性试验24.Q5D: Derivation and Characterization of Cell Substrates Used for Production of Biotechnological/Biological Products用于生产生物技术/生物产品的细胞底物的起源和特征描述25.Q5E: Comparability of Biotechnological/Biological Products Subject to Changes inTheir Manufacturing Process基于不同生产工艺的生物技术产品/生物产品的可比较性26.Q6: Specifications规格27.Q6A: Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances (including decision trees) 质量规格:新原料药和新制剂的检验程序和可接收标准:化学物质(包括决定过程)28.Q6B: Specifications: Test Procedures and Acceptance Criteria for29.Biotechnological/Biological Products质量规格:生物技术/生物产品的检验程序和可接收标准30.Q7: Good Manufacturing Practices (GMP)31.Q7A: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients活性药物成份的GMP指南32.Q8: Pharmaceutical Development药物研发33.Annex to Q8Q8附录34.Q9: Quality Risk Management质量风险管理35.Q10: Pharmaceutical Quality System药物质量体系二、ICH.安全性部分(Safety) 致癌试验1.S1A Guideline on the Need for Carcinogenicity Studies of Pharmaceuticals 药物致癌试验的必要性2.S1B Testing for Carcinogenicity of Pharmaceuticals 药物致癌试验3.S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals药物致癌试验的剂量选择4.S1C’药物致癌试验的剂量选择的附件:补充剂量限度和有关注释遗传毒性5.S2(R1) Guidance on Genotoxicity Testing and Data Interpretation forPharmaceuticals Intended for Human Use 人用药物的遗传毒性试验和数据分析指导原则6.S2A药物审评遗传毒性试验的特殊性指导原则7.S2B遗传毒性:药物遗传毒性试验标准组合药代8.S3A Note for Guidance on T oxicokinetics: The Assessment of Systemic Exposurein Toxicity Studies 毒代动力学指导原则:毒性研究中全身暴露的评价9.S3B Pharmacokinetics: Guidance for Repeated Dose TissueDistribution Studies药代动力学:重复给药的组织分布研究指导原则慢性毒性10.S4Duration of Chronic T oxicity Testing in Animals (Rodent and Non RodentToxicity Testing) 动物慢性毒性试验的周期(啮齿类和非啮齿类)生殖毒性11.S5(R2) Detection of T oxicity to Reproduction for Medicinal Products andToxicity to Male Fertility (the Addendum dated November 1995 has beenincorporated into the core guideline in November 2005 )12.S5A药品的生殖毒性检测13.S5B雄性生育力毒性其他14.S6Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals 生物技术药品的临床前安全性试验15.S7A Safety Pharmacology Studies for Human Pharmaceuticals 人用药物的安全性药理研究16.S7B The Non-clinical Evaluation of the Potential for Delayed VentricularRepolarization (QT Interval Prolongation) by Human Pharmaceuticals人用药延迟心室复极化(QT间期延长)潜在作用的非临床评价指导原则17.S8Immunotoxicity Studies for Human Pharmaceuticals人类药品的免疫毒性研究18.S9 Nonclinical Evaluation for Anticancer Pharmaceuticals 抗癌药物的临床前评价19.S10 Photosafety Evaluation三、ICH.临床部分(Efficacy)1.E1The Extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-T erm Treatment of Non-Life-Threatening Conditions 评价临床长期给药方案的安全性2.E2A Definitions and Standards for Expedited Reporting 快速报告的定义和标准3.E2B(R3) Data Elements for Transmission of Individual Case Safety Reports个体病例安全性报告传递的数据要素4.E2C Periodic Benefit-Risk Evaluation Report 上市药品定期安全性更新报告5.E2D Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting批准后安全性数据管理:快速报告的定义和标准6.E2E Pharmacovigilance Planning药物警戒计划7. E2F Development Safety Update Report8.E3Structure and Content of Clinical Study Reports 临床研究报告的结构与内容9.E4Dose-Response Information to Support Drug Registration 新药注册所需量-效关系的资料10.E5(R1)Ethnic Factors in the Acceptability of Foreign Clinical Data 对国外临床研究资料的种族因素的可接受性11.E6(R1) Good Clinical Practice: Consolidated Guideline 药品临床研究规范(GCP)一致性指导原则12.E7Studies in Support of Special Populations: Geriatrics 老年人群的临床研究13.E8General Considerations for Clinical Trials 临床试验的一般考虑14.E9Statistical Principles for Clinical Trials 临床试验统计原则15.E10Choice of Control Group and Related Issues in Clinical Trials 对照组的选择16.E11Clinical Investigation of Medicinal Products in the Pediatric Population 儿童人群的临床研究17.E12按治疗分类的各类药物临床评价E12 Principles for Clinical Evaluation of New Antihypertensive Drugs18.E14The Clinical Evaluation of QT/QT c Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs 非抗心律失常药物致QT/QT c间期延长及潜在心律失常作用的临床评价19.E15 Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding Categories20.E16 Biomarkers Related to Drug or Biotechnology Product Development: Context, Structure and Format of Qualification Submissions四、ICH.综合部分 (Multidisciplinary)1.M1医学术语Med DRA2.M2Electronic Transmission of Individual Case Safety Reports MessageSpecification (ICH ICSR DTD Version 2.1) companion document to E2B(R3)注册资料传递所需的电子代码3.M3Guidance on Nonclinical Safety Studies for the Conduct of Human ClinicalTrials and Marketing Authorization for Pharmaceuticals与临床研究有关的临床前研究的时间安排4.M4 Organisation of the Common Technical Document for the Registration ofPharmaceuticals for Human Use (Edited with Numbering and Section Header Changes, September 2002). Including the Annex : the Granularity Document(Revised November 2003).CTD(common technical document)(包括CTD、CTD-Q、CTD-S、CTD-E和eCTD)药品词汇的数据要素和标准5.M4Q (R1) The Common Technical Document for the Registration ofPharmaceuticals for Human Use: Quality (Edited with Numbering and Section Header Changes, September 2002)6.M4S (R2) The Common Technical Document for the Registration ofPharmaceuticals for Human Use: Safety (Edited with Numbering and SectionHeader Changes, September 2002)7.M4E (R1) The Common Technical Document for the Registration ofPharmaceuticals for Human Use: Efficacy (Edited with Numbering and Section Header Changes, September 2002)8.M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities inPharmaceuticals to Limit Potential Carcinogenic Risk Reference:1. 《ICH 药品注册的国际要求》2. /doc/d6990802.html,3./doc/d6990802.html,/health/Health/yx/yao/20 07-08-07/6326.html。
一种中药的作用和价值的英语作文
一种中药的作用和价值的英语作文The Multifaceted Effects and Inestimable Value of Banxia.In the vast pharmacopeia of traditional Chinese medicine, a remarkable herb stands out for its versatile therapeutic applications and profound medicinal significance: Banxia. This multifaceted botanical has been revered for centuries for its ability to alleviate a wide spectrum of ailments, earning it a cherished place in the healing traditions of the East.Botanical Identity and Traditional Usage.Banxia, also known by its botanical name Pinellia ternata, is a perennial herbaceous plant native to eastern Asia. Its main medicinal component is derived from the dried and processed rhizome, which possesses a pungent odor and a slightly bitter taste.In traditional Chinese medicine, Banxia has been employed for millennia to treat a diverse range of conditions, including respiratory ailments such as coughs, asthma, and bronchitis; digestive issues like nausea, vomiting, and diarrhea; and neurological disorders like dizziness and vertigo. Its versatility stems from its complex chemical composition, which includes alkaloids, terpenoids, and starch.Pharmacological Effects.Modern scientific research has substantiated many of the traditional uses of Banxia, revealing a host of pharmacological properties that contribute to its therapeutic efficacy.Expectorant and Anti-inflammatory: Banxia exhibits expectorant and anti-inflammatory effects, effectively reducing phlegm production and soothing inflamed respiratory tissues. This makes it an ideal remedy for conditions like coughs and bronchitis.Anti-nausea and Anti-emetic: The herb contains compounds that act as anti-nausea and anti-emetics, suppressing the vomiting reflex and preventing nausea. Itis often used to alleviate these symptoms associated with motion sickness, chemotherapy, and other conditions.Anti-diarrheal: Banxia's astringent properties help to reduce diarrhea by regulating intestinal motility and promoting fluid absorption.Neurological Effects: Some studies suggest that Banxia may have neuroprotective and anti-vertigo effects, potentially benefiting conditions like Alzheimer's disease and Meniere's disease.Clinical Applications.The therapeutic applications of Banxia are numerous and well-documented. It is commonly used in the following clinical scenarios:Respiratory Conditions: Banxia is a key ingredient inmany herbal formulas for treating coughs, asthma, bronchitis, and other respiratory ailments. Its expectorant and anti-inflammatory properties help to clear congestion and soothe airways.Gastrointestinal Disorders: Banxia is employed to alleviate nausea, vomiting, and diarrhea. It is often combined with other herbs to enhance its efficacy.Neurological Conditions: Banxia may be beneficial in reducing dizziness and vertigo, potentially improving balance and coordination.As an Adjuvant: Banxia is frequently used as an adjuvant in herbal formulas to enhance the therapeutic effects of other herbs. It promotes absorption, reduces toxicity, and modulates the overall action of the formula.Combinations and Preparations.Banxia is rarely used alone in traditional Chinese medicine. It is often combined with other herbs to createsynergistic formulas that target specific conditions. Some common combinations include:For cough and asthma: Banxia is often combined with almonds, ephedra, and ginger.For nausea and vomiting: Banxia is frequently paired with ginger, mint, and licorice.For diarrhea: Banxia is combined with atractylodes, angelica, and ginseng.Banxia can be prepared in various forms, including decoctions, pills, powders, and tinctures. The specific preparation depends on the condition being treated.Safety Considerations.Banxia is generally considered safe for most people when used in appropriate doses. However, it is crucial to note the following precautions:Contraindications: Banxia should be avoided during pregnancy and lactation.Drug Interactions: Banxia may interact with certain medications, such as blood thinners. It is advisable to consult with a healthcare professional before using Banxiaif you are taking any medications.Toxicity: Excessive consumption of Banxia can causeside effects like skin irritation, diarrhea, and vomiting.Conclusion.Banxia is a time-honored medicinal herb with a wide range of therapeutic applications. Its multifaceted effects, from expectorant to anti-emetic to neurological, make it a valuable addition to the traditional Chinese medicine armamentarium. When used appropriately, Banxia caneffectively alleviate a variety of ailments and promote overall health and well-being. However, it is essential to exercise caution, adhere to recommended dosages, and seek professional advice when necessary. By respecting thewisdom of traditional Chinese medicine and embracing the power of nature's remedies, we can harness the healing benefits of Banxia and cultivate a healthier and more balanced life.。
版《中国药典》收载的含麝香、牛黄中药制剂的质量标准探讨
版《中国药典》收载的含麝香、牛黄中药制剂的质量标准探讨一、本文概述Overview of this article随着现代科技的飞速发展和中医药理论的日益深入,中药制剂的质量标准已经成为业内关注的热点。
《中国药典》作为我国的国家药品标准,对于保障药品质量、促进中药现代化和国际化具有重要意义。
本文旨在探讨《中国药典》中收载的含麝香、牛黄中药制剂的质量标准,分析其在质量控制、药效评价以及临床应用等方面的现状与挑战,以期为提高中药制剂的整体质量提供参考。
With the rapid development of modern technology and the increasing depth of traditional Chinese medicine theory, the quality standards of traditional Chinese medicine preparations have become a hot topic of concern in the industry. The Chinese Pharmacopoeia, as the national drug standard in China, is of great significance in ensuring drug quality, promoting the modernization and internationalization of traditional Chinese medicine. This article aims to explore the quality standardsof traditional Chinese medicine preparations containing musk and bezoar included in the Chinese Pharmacopoeia, analyze their current status and challenges in quality control, efficacy evaluation, and clinical application, in order to provide reference for improving the overall quality of traditional Chinese medicine preparations.麝香和牛黄作为传统中药材,具有独特的药理作用和广泛的应用价值。
中医学英文词汇汇总
一、绪论中医学TCM(Traditional Chinese Medicine),中医学理论体系的形成Origination of TCM, 形成formation, 发展development 中医学理论体系的基本特点The basic characteristic of Traditional Chinese Medicine theory整体观the whole concept, 辨证论治syndrome differentiation and treatment第一章阴阳五行学说阴阳Yin-yang , 阴阳的特性the property of yin-yang阴阳之间的相互关系Interaction between yin and yang阴阳对立制约Opposition of yin and yang阴阳互根互用Interdependence between yin and yang阴阳消长平衡Wane and Wax between yin and yang阴阳相互转化Mutual transformation between yin and yang阴阳学说在中医学中的应用The applications of the theory of yin-yang in TCM说明人体的组织结构Explanation of the histological structure of the human body 解释人体的生理功能Explanation of the physiology function activity of the human body阐释病理变化Explanation of pathogenesis阴阳偏盛Relative predominance of yin or yang阳偏盛Relative predominance of yang阴偏盛Relative predominance of yin阴阳偏衰Relative decline of yin or yang阳偏衰Relative decline of yang阴偏衰Relative decline of yinthe five elements, 五行五行特性the five elements property第二章中医学的生理观藏象“Zangxiang”,五脏five Zang-organs, 六腑six fu-organs,生理功能the physiological functions , 气qi, 血blood , 津液body fluid,气的生成、运动和分类the production ,moving and classification of qi,血的生成和运行the production and circulation of blood津液的生成、输布和排泄the production and transportation and metabolism of body fluid.气、血、津液的功能The physiological functions of qi, blood and body fluid心The heart,主血脉Governing blood主神志controlling the mind在体合脉governs the vessels开窍于舌opens into the tongue其华在面External manifestation on the face肝The liver,主疏泄To dredge and regulate, 主藏血Storing blood在体合筋The liver governing the tendons其华在爪The external manifestation of the liver on the nails开窍于目The liver opening into the eyes脾the spleen,主运化To govern the transportation and transformation主统血To command blood, 主升elevating在体合肌肉,主四肢the spleen governing the muscles and the four limbsThe spleen opening into the mouth开窍于口.其华在唇The external manifestation on the lip肺The lung,主气,司呼吸Dominating qi,controlling the respiratory movement主宣发、肃降dispersing and descending通调水道The regulation of water passage朝百脉、主治节?the lung is connected with all the vessels, regulation the qi activity in the whole body在体合皮the lung governing the skin其华在毛Eexternal manifestation on the body hair开窍于鼻The lung opening into the nose肾The kidney,藏精store essence, 主水To govern water, 主纳气To govern reception of qi在体合骨The kidney governing the bones开窍于耳及二阴The kidney opening into the ears, the external genitals and the anus 其华在发External manifestation on the hair胆The gallbladder, 贮藏和排泄胆汁store and excrete the bile胃The stomach, 受纳、腐熟水谷receive and digest food主通降?the stomach functions to descend?,?unobstructed condition小肠The small intestine, 受盛化物To receive the chime and transform泌别清浊To separate the lucid from the turbid大肠The large intestine, 主传化糟粕transmitting and excreting the waste of food storing and discharging urine The bladder ,膀胱气的生成The production of qi气的运动The moving of qiThe physiological functions of qi气的功能推动作用Propelling function温煦作用Warming function防御作用Protecting and defencive function固摄作用Fixating function气化作用Qi-transforming function元气primordial qi, 宗气pectoral qi, 营气nutrient-qi, 卫气defensive qi第三章中医学的病理观病因 Causes of disease病因的概念及分类concept, classification of causes of disease.六淫的概念concept of six pathogenic factors;,,六淫致病的共同特点the general pathogenic characters of six pathogenic factors;六淫(风、寒、暑、湿、燥、火)的性质与致病特点nature, pathogenic characters of every six pathogenic factors(including wind,cold,Summer-heat,Dampness,Dryness,Heat (fire))主要的临床表现main clinic manifestations风Wind其性开泄,易袭阳位Wind tend to float, disperse, go upward attack the upper and outside parts风性善行而数变wind tends to move and change风为百病之长,易夹杂其他外感之邪Wind tends to be complicated by other pathogenic factors寒Cold易伤阳气Cold tends to impair yang寒性凝滞Cold tends to coagulate寒性收引Cold tends to contract暑Summer-heatSummer-heat is hot其性炎热暑性升散,耗气伤津Summer-heat tends to disperse and elevate,consume the qi and body fluid暑多夹湿Summer-heat often complicated by dampness湿Dampness湿性重浊dampness is heavy and turbid湿易阻遏气机dampness tends to block qi湿性黏滞dampness is sticky and stagnant湿性趋下, 易袭阴位dampness tends to move downward,attack the lower and inside parts燥Dryness燥易伤津Dryness consume the body fluid燥性干涩Dryness is xerotic and unsmooth燥易伤肺Dryness tends to impair the lung火Heat (fire)其性炎上Heat(fire) tends to flame up易伤津耗气Heat(fire) tends to consume qi and impair body fluid易生风动血Heat(fire) tends to produce wind and disturb blood易致肿疡Heat(fire) tends to cause swelling and ulceration七情内伤的概念、The concept of internal impairment due to the seven emotions,七情致病的特点the pathogenic characters of the seven emotions痰饮、瘀血的概念、形成及致病特点The basic concept, the formation and the pathogenic characteristics of phlegm ,rheum and blood stasis痰饮phlegm ,rheum 瘀血blood stasis发病的基本原理The pathogenesis of occurrence of disease in TCM病机的概念,The concept of mechanism of pathological changes;病机the mechanism of pathological changes;邪正盛衰predomination and decline of pathogenic factors and healthy qi;阴阳失调imbalance between yin and yang;气血津液失常disorder of qi, blood and body fluid.第四章中医诊断疾病的方法中医诊法The concept of the TCM diagnostic methods中医诊断的理论依据the theory foundation of the TCM diagnostic methods.望神Inspection of spirit, 望色Inspection of complexion, 望排出物Inspection of excreta ,望舌Inspection of tongue,Existence of spirit (得神),Lack of spirit(少神),Loss of spirit (失神)False spirit(假神)Normal complexion 常色Morbid complexion 病色Red colour ,White colour ,Yellow colour, Bluish colour,Blackish colour临床意义clinical significance ;望舌的方法Methods for inspection of tongue舌苔tongue coat舌红red tongue淡白舌/舌淡Light-whitish tongue青紫舌Cyanotic and purplish tongue问诊inquiry, 主诉chief complaint, 病史history of present illness问现在症inquiry of the present symptomsAversion to cold and fever(恶寒发热)Cold sensation without fever(但寒不热)Fever without cold sensation(但热不寒)Alternate cold and fever(寒热往来)诊脉的部位与方法The Regions and methods for taking pulse脉诊taking pulse, 正常脉象normal pulseCunkou(寸口)cun(寸), guan(关),chi(尺).辨证的概念The concept of differentiation of syndrome表里辨证External and internal differentiation of syndromes,External syndromes, 表证.里证internal syndromes,寒热辨证cold and heat differentiation of syndromes,寒证cold f syndromes,热证heat syndromes,虚实辨证asthenia and sthenia differentiation of Syndromes,虚证asthenia Syndromes,实证sthenia Syndromes,临床特点clinical character and difference.八纲辨证Syndromes differentiation with eight principles气血津液辨证syndrome differentiation with qi, blood and body fluid,第五章中医学的防治原则治则治法therapeutic methodstherapeutic principles ,正治反治Contrary treatment, Routine treatment ,治本treat “ben”(deal with the root cause)治标Treating biao(acute symptoms bring on great suffering to the patients, or threaten life or tend to transmit and change) in emergency ,扶正与祛邪Strengthening healthy qi and eliminating pathogenic factors,调整阴阳Regulation of yin and yang,三因制宜Abidance by individuality, locality and seasons.第六章中药基本知识中药Chinese Medicinal Herbs四气four properties、寒热温凉cold, hot, warm, cool五味five flavors、辛、甘、酸、苦、咸pungent, sweet, sour, bitter and salty.、the action of lifting, lowering, floating and sinking,升降浮沉.归经channel tropism、毒性toxicity中药的配伍、用药禁忌Contraindication and Compatibility of Chinese Medicinal Herbs中药的剂量Dosage of Chinese Medicinal Herbs第七章方剂基本知识方剂的组成原则The principle of the composition of prescriptions,Monarch drug (jun) 君Minister drug (chen) 臣Adjuvant drug (zuo) 佐Guide drug (shi) 使组成变化the modification of the composition of a prescription.方剂的组成、用法、功效、临床应用、方解:Ingredients, administration, function,clinical application and elucidation of the prescriptions第二章中医学的生理观第三节经络经络the meridians;十二经脉twelve regular meridians十二经脉走向与交接规律direction, joint law of the twelve channels、十二经脉循行分布规律distributing law of the twelve channels ,十二经脉表里络属关系exterior-interior relationship of the twelve channels ,十二经脉流注方向和次序等flowing direction and order of the twelve channels;第八章针灸学基本知识第二节刺灸方法刺法(针法)Acupuncture techniques; 进针Needling methods (insertion methods, Needling manipulation methods)得气arrival of Qi针刺意外和防治处理Management of possible accidents (emphasize 晕针fainting) 灸法moxibustion,第八章针灸学基本知识第一节腧穴腧穴概念;腧穴分类;腧穴定位方法;腧穴的作用the point/acupoint (definition/concept, classification, location method, function)腧穴的定位、归经、基本主治功能:location, channel tropism and the basic special treatment function of the point/acupoint下列腧穴的定位、基本主治功能:手太阴肺经:列缺;The lung channel of Hand-Taiyin: LieQue (Lu7)手阳明大肠经:合谷;The large intestine channel of Hand-Yangming: Hegu (LI4) 足阳明胃经:足三里;The stomach channel of Foot-Yangming: Zusanli (ST36)足太阴脾经:三阴交;The spleen channel of Foot-Taiyin: Sanyinjiao (SP6)手少阴心经:神门;The heart channel of Hand-shaoyin: Shenmen (HT7)手太阳小肠经:听宫;The small intestine channel of Hand-taiyang: Tinggong (SI19) 足太阳膀胱经:委中;The urinary Bladder channel of Foot-Taiyang:Weizhong(BL40),足少阴肾经:涌泉;The Kidney channel of Foot-shaoyin: Yongquan(KI 1)手厥阴心包经:内关;The Pericardium channel of hand-Jueyin: Neiguan (PC6) Hand-Shaoyang:of channel ) (Sanjiao warmer triple The 手少阳三焦经:外关;Waiguan (SJ5 ),足少阳胆经:风池;The Gall Bladder channel of Foot-shaoyang: Fengchi (GB20) 足厥阴肝经:太冲;The Liver channel of Foot-Jueyin: Taichong (LR3)任脉:关元、膻中;The Ren channel :Guanyuan (RN4), Tanzhong (RN17)督脉:大椎、人中;The Du channel : Mingmen(GV 4), Dazhui (DU14), Shuigou (DU26),经外奇穴:印堂、太阳;Extraordinary acupoints: Yintang(EX-HN 3), Taiyang(EX-HN 5)。
ICH-GCP中英文对照(完整)
ICH-GCP中英文对照(完整)ICH 三方协调指导原则 E6 ICH GCP指导原则INTRODUCTION前言Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the participation of human subjects. Compliance with this standard provides public assurance that the rights, safety and well-being of trial subjects are protected, consistent with the principles that have their origin in the Declaration of Helsinki, and that the clinical trial data are credible.临床试验管理规范(GCP)是设计、实施、记录和报告设计人类对象参加的试验国际性伦理和科学质量标准。
遵循这一标准为保护对象的权利、安全性和健康,为与源于赫尔辛基宣言的原则保持一致以及临床试验数据的可信性提供了公众保证。
The objective of this ICH GCP Guideline is to provide a unified standard for the European Union (EU), Japan and the United States to facilitate the mutual acceptance of clinical data by theregulatory authorities in these jurisdictions. ICH-GCP指导原则的目的是为欧盟、日本和美国提供统一的标准,以促进这些管理当局在其权限内相互接受临床数据。
- 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。
CLINICAL AND MEDICINAL APPLICATIONS OF RESVERATROL: A REVIEWSatyanand Tyagi 1*, Gunjan Singh 2, Anamika Sharma 3, Gulshan Aggarwal 4.1Department of Pharmaceutical Chemistry, K.N.G.D Modi Institute of Pharmaceutical Education & Research, Modinagar,Ghaziabad (dt), U.P, India-201204.2Associate Labeling, Ranbaxy Laboratories Ltd, Gurgaon (dt), Haryana, India-122001.3Department of Pharmacy practice, Jamia Hamdard University, Hamdard Nagar, New Delhi, India-110062. 4Department of Biotechnology, Deakin University, Geelong campus, Waurn Ponds, Victoria, Australia- 3210.*Email: sntyagi9@ABSTRACTResveratrol is a flavonol belonging to the group of flavonoids. It is produced by the plant as a defence against diseases. Resveratrol is present in many plants and fruits, including red grapes, eucalyptus, spruce, blueberries, mulberries, peanuts, giant knotweed. Resveratrol is an antioxidant but its antioxidant properties are weaker that those of quercetin and epicatechin. It has anticancer properties and inhibits lipid peroxidation of low-density lipoprotein and prevents the cytotoxicity of oxidized LDL. Resveratrol also increases the activity of some antiretroviral drugs in vitro. Resveratrol protects our heart and blood vessels by directly scavenging oxidants, which could cause oxidation of lipids, and by preventing apoptosis of endothelial cells. It may also help to prevent heart damage after a cardiac arrest. Reduced platelet aggregation has been attributes to resveratrol, thereby reducing the risk of atherosclerosis. Tests with animals have shown that that high food intake reduces lifespan. One study showed that resveratrol was able to able to increase the life span of mice on a high calorie diet. Many studies on animals have shown antitoxic effects of resveratrol. Resveratrol was able to reverse damages caused by the administration of the chemotherapeutic drug bleomycin. Resveratrol also helped to reduce brain damage and oxidative damage of the liver during ethanol intoxication. It also reduced kidney damage of rats treated with the antibiotic gentamicin. In the present article, we have concentrated on potential clinical and medicinal applications of Resveratrol. The aim of present article is to provide in depth knowledge about clinical utility of Resveratrol in current scenario.Keywords: Resveratrol, trans-resveratrol, phytoalexin, 3, 4’, 5-Stilbenetriol, trans-3, 5, 4’-Trihydroxystilbene.INTRODUCTONResveratrol is a phytoalexin produced naturally by several plants when under attack by pathogens such as bacteria or fungi. Resveratrol is currently a topic of numerous animal and human studies into its effects. The effects of resveratrol on the lifespan of many model organisms remain controversial, with uncertain effects in fruit flies, nematode worms 1, and short-lived fish. In mouse and rat experiments, anti-cancer, anti-inflammatory, blood-sugar-lowering and other beneficialcardiovascular effects of resveratrol have been reported. Most of these results have yet to be replicated in humans. In the only positive human trial, extremely high doses (3–5 g) of resveratrol in a proprietary formulation have been necessary to significantly lower blood sugar 2. Despite mainstream press alleging resveratrol's anti-aging effects, there is little present scientific basis for the application of these claims to mammals. Resveratrol is found in the skin of red grapes and is a constituent of red wine, but apparently not in sufficient amounts to explain the French Paradox. Resveratrol has also been produced by chemical synthesis 3 and is sold as a nutritional supplement derived primarily from Japanese knotweed.Trans-resveratrolRECENT STUDIES Life ExtensionThe groups of Howitz and Sinclair reported in 2003 in the journal Nature that resveratrol significantly extends the lifespan of the yeast Saccharomyces cerevisiae 4. Later studies conducted by Sinclair showed that resveratrol also prolongs the lifespan of the worm Caenorhabditis elegans and the fruit fly Drosophila melanogaster 5. In 2007, a different group of researchers were able to reproduce Sinclair's results with Caenorhabditis elegans 6, but a third group could not achieve consistent increases in lifespan of D. melanogaster or C. elegans. In 2006, Italian scientists obtained the first positive result of resveratrol supplementation in a vertebrate.Using a short-lived fish, Nothobranchius furzeri, with a median life span of nine weeks, they found that a maximal dose of resveratrol increased the median lifespan by 56%. Compared with the control fish at nine weeks that is by the end of control fish’s life the fish supplemented with resveratrol showed significantly higher general swimming activity and better learning to avoid an unpleasant stimulus. The authors noted a slight increase of mortality in young fish caused by resveratrol and hypothesized that it is its weak toxic action that stimulated the defense mechanisms and resulted in the life span extension 7. Later the same year, Sinclair reported that resveratrol counteracted the detrimental effects of a high-fat diet in mice. The high fat diet was compounded by adding hydrogenated coconut oil to the standard diet; it provided 60% of energy from fat, and the mice on it consumedabout 30% more calories than the mice on standard diet. Both the mice fed the standard diet and the high-fat diet plus 22 mg/kg resveratrol had a 30% lower risk of death than the mice on the high-fat diet. Gene expression analysis indicated the addition of resveratrol opposed the alteration of 144 out of 153 gene pathways changed by the high-fat diet. Insulin and glucose levels in mice on the high-fat + resveratrol diet were closer to the mice on standard diet than to the mice on the high-fat diet. However, addition of resveratrol to the high-fat diet did not change the levels of free fatty acids and cholesterol, which were much higher than in the mice on standard diet8. A further study by a group of scientists, which included Sinclair, indicated that resveratrol treatment had a range of beneficial effects in elderly mice but did not increase the longevity of ad libitum–fed mice when started midlife9.Cancer preventionIn 1997, Jang reported that topical resveratrol applications prevented skin cancer development in mice treated with a carcinogen10. There have since been dozens of studies of the anti-cancer activity of resveratrol in animal models11. No results of human clinical trials for cancer have been reported12. However, clinical trials to investigate the effects on colon cancer and melanoma (skin cancer) are currently recruiting patients.In vitro resveratrol interacts with multiple molecular targets, and has positive effects on the cells of breast, skin, gastric, colon, esophageal, prostate, and pancreatic cancer, and leukemia. However, the study of pharmacokinetics of resveratrol in humans concluded that even high doses of resveratrol might be insufficient to achieve resveratrol concentrations required for the systemic prevention of cancer13. This is consistent with the results from the animal cancer models, which indicate that the in vivo effectiveness of resveratrol is limited by its poor systemic bioavailability14, 15. The strongest evidence of anti-cancer action of resveratrol exists for tumors it can come into direct contact with, such as skin and gastrointestinal tract tumors. For other cancers, the evidence is uncertain, even if massive doses of resveratrol are used.Thus, topical application of resveratrol in mice, both before and after the UVB (Ultraviolet B or medium wave) exposure, inhibited the skin damage and decreased skin cancer incidence. However, oral resveratrol was ineffective in treating mice inoculated with melanoma cells. Resveratrol given orally also had no effect on leukemia and lung cancer16; however, injected intraperitoneally, 2.5 or 10 mg/kg of resveratrol slowed the growth of metastatic Lewis lung carcinomas in mice17. Resveratrol (1 mg/kg orally) reduced the number and size of the esophageal tumors in rats treated with a carcinogen18. In several studies, small doses (0.02–8 mg/kg) of resveratrol, given prophylactically, reduced or prevented the development of intestinal and colon tumors in rats given different carcinogens.Resveratrol treatment appeared to prevent the development of mammary tumors in animal models; however, it had no effect on the growth of existing tumors. Paradoxically, treatment of pre-pubertal mice with high doses of resveratrol enhanced formation of tumors. Injected in high doses into mice, resveratrol slowed the growth of neuroblastomas.Other applicationsJohan Auwerx (at the Institute of Genetics and Molecular and Cell Biology in Illkirch, France) and coauthors published an online article in the journal Cell in November, 2006. Mice fed resveratrol for fifteen weeks had better treadmill endurance than controls. The study supported Sinclair's hypothesis that the effects of resveratrol are indeed due to the activation of the Sirtuin 1 gene.Nicholas Wade's interview-article with Dr. Auwerx19 states that the dose was 400 mg/kg of body weight (much higher than the 22 mg/kg of the Sinclair study). For an 80 kg (176 lb) person, the 400 mg/kg of body weight amount used in Auwerx's mouse study would come to 32,000 mg/day. Compensating for the fact that humans have slower metabolic rates than mice would change the equivalent human dose to roughly 4571 mg/day. Again, there is no published evidence anywhere in the scientific literature of any clinical trial for efficacy in humans. There is limited human safety data. Long-term safety has not been evaluated in humans. In a study of 123 Finnish adults, those born with certain increased variations of the SIRT1 gene had faster metabolisms, helping them to burn energy more efficiently—indicating that the same pathway shown in the lab mice works in humans. Neuroprotective effectsIn November 2008, researchers at the Weill Medical College of Cornell University reported that dietary supplementation with resveratrol significantly reduced plaque formation in animal brains, a component of Alzheimer and other Neurodegenerative diseases20. In mice, oral resveratrol produced large reductions in brain plaque in the hypothalamus (-90%), striatum (-89%), and medial cortex (-48%) sections of the brain. In humans it is theorized that oral doses of resveratrol may reduce beta amyloid plaque associated with aging changes in the brain. Researchers theorize that one mechanism for plaque eradication is the ability of resveratrol to chelate (bind) copper. The neuroprotective effects have been confirmed in several animal model studies21-25.Anti-inflammatory effectsThe anti-inflammatory effects of resveratrol have been demonstrated in several animal model studies. In a rat model of carrageenan-induced paw edema, resveratrol inhibited both acute and chronic phases of the inflammatory process26. Similarly, preincubation with resveratrol decreased arachidonic acid release and COX-2 induction in mouse peritoneal macrophages stimulated with tumor promoter PMA, ROI, or lipopolysaccharides (LPS)27. In an experimental rabbit inflammatory arthritis model, resveratrol has showed promise as a potential therapy for arthritis. When administered to rabbits with induced inflammatory arthritis, resveratrol protected cartilage against the progression of inflammatory arthritis28.Cardioprotective effectsIt has long been known that moderate drinking of red wine reduces the risk of heart disease29. Studies suggest that resveratrol in red wine may play an important role in this phenomenon30. It achieves the effects by the following functions: (1) Inhibition of vascular cell adhesion molecule expression; (2) Inhibition of vascular smooth muscle cell proliferation; (3) Stimulation of endolethelial nitric oxide synthase (eNOS) Activity; (4) Inhibition of platelet aggregation; (5) Inhibition of LDL peroxidation; The cardioprotective effects of resveratrol are also theorized to be a form of preconditioning—the best method of cardioprotection, rather than direct therapy31. Chemical and Physical PropertiesResveratrol (3, 5, 4’-trihydroxystilbene) is a polyphenolic phytoalexin. It is a stilbenoid, a derivate of stilbene, and is produced in plants with the help of the enzyme stilbene synthase. It exists as two geometric isomers: cis- (Z) and trans- (E). The trans- form can undergo isomerisation to the cis- form when exposed to ultraviolet irradiation32. Trans-resveratrol in the powder form was found to be stable under "accelerated stability" conditions of 75% humidity and 40 degrees C in the presence of air. Resveratrol content also stayed stable in the skins of grapes and pomace taken after fermentation and stored for a long period.Acknowledgement: The authors are thankful to the Management of K.N.G.D Modi Institute of Pharmaceutical Education & Research for providing facilities to utilize the library and internet in the college.REFERENCES1.Bass TM, Weinkove D, Houthoofd K, Gems D,Partridge L, Effects of resveratrol on lifespan in Drosophila melanogaster and Caenorhabditis elegans, Mechanisms of ageing and development, 128 (10), 2007, 546–52.2.Elliott PJ, Jirousek, M. Sirtuins, Novel targets formetabolic disease, Current Opinion in Investigational Drugs, 9 (4), 2008, 1472–78.3.Farina A, Ferranti C, Marra C, An improvedsynthesis of resveratrol, Nat. Prod. Res, 20 (3), 2006, 247–52.4.Howitz KT, Bitterman KJ, Cohen HY, LammingDW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA, "Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan", Nature, 425 (6954), 2003, 191–196.5.Wood JG, Rogina B, Lavu1 S, Howitz K, HelfandSL, Tatar M, Sinclair D, "Sirtuin activators mimic caloric restriction and delay aging in metazoans" , Nature, 430 (7000), 2004, 686–89.6.Gruber J, Tang SY, Halliwell B, "Evidence for atrade-off between survival and fitness caused byresveratrol treatment of Caenorhabditis elegans", Ann N Y Acad Sci, 1100, 2007, 530–42.7.Valenzano DR, Terzibasi E, Genade T, Cattaneo A,Domenici L, Cellerino A, "Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate", Current Biology, 16 (3), 2006, 296–300.8.Baur JA, Pearson KJ, Price NL, Jamieson HA, LerinC, Kalra A, Prabhu VV, Sinclair DA, "Resveratrol improves health and survival of mice on a high-calorie diet", Nature, 444 (7117), 2006, 337–42 . 9.Pearson KJ, "Resveratrol delays age-relateddeterioration and mimics transcriptional aspects of dietary restriction without extending life span", Cell Metab, 8 (2), 2008, 157–68.10.Jang M, Cai L, Udeani GO, Slowing KV, ThomasCF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM, "Cancer chemopreventive activity of resveratrol, a natural product derived from grapes", Science, 275 (5297), 1997, 218–20.11.Baur JA, Sinclair DA, "Therapeutic potential ofresveratrol: the in vivo evidence", Nat Rev Drug Discov, 5 (6), 2006, 493–506.12.Athar M, Back JH, Tang X, "Resveratrol: a reviewof preclinical studies for human cancer prevention", Toxicol. Appl. Pharmacol, 224 (3), 2007, 274–83.13.Boocock DJ, Faust GE, Patel KR, "Phase I doseescalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent", Cancer Epidemiol.Biomarkers Prev, 16 (6), 2007, 1246–52.14. Niles RM, Cook CP, Meadows GG, Fu YM,McLaughlin JL, Rankin GO, "Resveratrol is rapidly metabolized in athymic mice and does not inhibit human melanoma xenograft tumor growth", J.Nutr, 136 (10), 2006, 2542–6.15.Wenzel E, Soldo T, Erbersdobler H, Somoza V,"Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats", Mol Nutr Food Res, 49 (5), 2005, 482–94.16.Gao X, Xu YX, Divine G, Janakiraman N, ChapmanRA, Gautam SC, "Disparate in vitro and in vivo antileukemic effects of resveratrol, a natural polyphenolic compound found in grapes", J.Nutr, 132 (7), 2002, 2076–81.17.Kimura Y, Okuda H, "Resveratrol isolated fromPolygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice", J. Nutr, 131 (6), 2001, 1844–49.18.Li ZG, Hong T, Shimada Y, Komoto I, Kawabe A,Ding Y, Kaganoi J, Hashimoto Y, Imamura M, "Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344rats by resveratrol", Carcinogenesis, 23 (9), 2002, 1531–36.gouge M, Argmann C, Gerhart-Hines,"Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha", Cell, 127(6), 2006, 1109–22.20.T. S. Anekonda, “Resveratrol—a Boon for TreatingAlzheimer’s disease?” Brain Res Rev, 52, 2006, 316-326.21. M. Sharma, Chronic Treatment with TransResveratrol Prevents Intracerebroventricular Streptozotocin Induced Cognitive Impairment and Oxidative Stress in Rats, Life Sci, 71, 2002, 2489-2498.22.P. Kumar, Effect of Resveratrol on 3-NitropropionicAcid-induced Biochemical and Behavioural Changes: Possible Neuroprotective Mechanisms, Behav. Pharmacol, 17, 2006, 485-492.23. Y. B. Yang, Effects of Resveratrol on SecondaryDamages after Acute Spinal Cord Injury in Rats, Acta. Pharmacol. Sin, 24, 2003, 703-710.24. K. Sinha, Protective Effect of Resveratrol againstOxidative Stress in Middle Cerebral Artery Occlusion Model of Stroke in Rats, Life Sci, 71, 2002, 655-65. 25. M. Gentilli, Resveratrol Decreases HyperalgesiaInduced by Carrageenan in the Rat Hind Paw, Life Sci, 68, 2001, 1317–1321.26.S. H. Tsai, Suppression of Nitric Oxide Synthase andthe Down-regulation of the Activation of NFkappaB in Macrophages by Resveratrol, Br. J. Pharmacol, 126, 1999, 673-680.27.N. Elmali, Effects of Resveratrol in InflammatoryArthritis, Inflammation, 30, 2007, 1-6.28. Paul E. Szmitko, Red Wine and Your Heart,Circulation 111, 2005, 10-11.29.P. Kopp, Resveratrol, a Phytoestrogen Found in RedWine. A Possible Explanation for the Conundrum of the ‘French paradox’? European Journal of Endocrinology, 138, 1998, 619-620.30.Asensi M, Medina I, Ortega, Inhibition of cancergrowth by resveratrol is related to its low bioavailability, Free Radic. Biol. Med, 33 (3), 2002, 387–98.muela-Raventos, RM; Romero-Perez, Ana I.;Waterhouse, Andrew L.; De La Torre-Boronat, M.Carmen, Direct HPLC Analysis of cis- and trans-Resveratrol and Piceid Isomers in Spanish Red Vitis vinifera Wines , J. Agric. Food Chem,43 (43), 1995, 281–283.************。